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ABSTRACT 
Schistosomiasis, caused by Schistosoma mansoni, is responsible for infecting 
approximately 200 million people worldwide, mostly from low-income and middle-income 
populations; it is a key neglected tropical parasitic disease, second only to malaria as the 
most devastating parasitic disease in the world.  An infection is initiated when the cercarial 
form of the parasite  is released from its intermediary invertebrate host, a Biomphalaria snail, 
into the surrounding fresh water. Cercariae are non-feeding, free swimming, extremely 
infectious, highly motile schistosomal stage  with bifurcated tails and they penetrate the 
mammalian skin tail-first, thus infecting the human host. Post attachment, the cercariae sheds 
its tail and the resulting schistosomule continues to develop within the host circulatory 
system. The parasites travel to the hepatic system, where they transform into adult worms, 
mate and lay eggs, most of which are excreted through the host’s excretory system and the 
rest accumulating within the internal organs of the body. The spread of schistosomiasis relies 
heavily on the motility of the cercariae before human infection, as well as the movement of 
the schistosomules through the human body, post infection. For my doctoral dissertation, I 
have focused on the aspect of motility  of the S.mansoni worms pre and post infection. The 
first part of my research deals with the design and development of a sensitive, simple, cheap 
biological assay i.e. a microfluidic platform to study the movement of the schistosomules as 
they travel through the host circulatory system. The complete navigation and the kinetics of 
the movement of the juvenile worms through the convoluted pulmonary, blood and hepatic 
vessels within the host remains largely unexplored. We believe that this novel approach will 
provide a highly efficient method for screening potential anti-schistosomal compounds and 
improving motility assays. The second part of my research concentrates on the qualitative 
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and quantitative proteomic analysis of the cercarial tails and cercarial bodies. Using 
mechanical separation of cercarial tails and bodies, and mass spectrometric analyses, we have 
identified a total of 945 proteins in the combined cercarial proteome from 4 independent 
samples: 791 proteins in the cercarial tails and 645 proteins from the somule bodies. Gene 
oncology analysis was conducted on the obtained proteomic data, and the peptide hits were 
classified based on molecular function, biological function and subcellular location. In 
conclusion, I believe that by preventing the motility of the parasitic worms at different stages 
of the life cycle is a novel, previously unexplored route for investigating potential drug 
targets which could interrupt the spread of the disease.
 
1 
CHAPTER 1.    INTRODUCTION 
1.1.Schistosomiasis Is an Important NTD 
Neglected tropical diseases (NTDs) are defined as a large, diverse group of infectious 
diseases, that are mostly present in tropical and subtropical countries [1-3]. According to the 
World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), 
more than one billion people, mostly from low-income and middle-income populations, are 
affected by NTDs in at least 149 countries [1-6]. Residents living in places without access to 
safe water, poor sanitation, contact with unhygienic contaminated water, limited education, 
food insecurity and lack of access to basic health services are prone to such infections [2, 4, 
6]. NTDs are caused by a wide variety of microorganisms and metazoan pathogens which 
include viruses, bacteria, protozoa and helminth parasites [2, 3]. Helminth diseases are 
caused by two groups: nematodes and platyhelminths [7]. Schistosomiasis is an endemic 
NTD which is second-only to malaria as the most devastating parasitic disease in the world 
[8-11]. It is caused by a diverse group of helminth trematode parasites called schistosomes, 
which belong to the family Schistosomatidae within the phylum platyhelminthes [5, 12, 13].  
This parasitic disease is responsible for the loss of 1.53 million disability-adjusted life 
years (DALYs) and up to 280,000 deaths annually in sub-Saharan Africa alone [14-16]. 
According to reports filed by the National Institute of Allergy and Infectious Diseases 
(NIAID) and CDC, these parasites are not found in the United States. Human schistosomiasis 
is distributed throughout Africa including sub-Saharan Africa, the Sudan, the Middle East 
and Egypt; in South America the disease is found in Brazil, Suriname and Venezuela; the 
Caribbean (for example, the Dominican Republic, Guadeloupe, Martinique and Saint Lucia); 
parts of China and South east Asia which includes Cambodia, Vietnam and Laos [3, 5, 9]. In 
 
2 
regions of high transmission, 60-80% of school-aged children and 20-100% of adults can be 
infected [4, 6, 7].  In 2014, the European Center of Diseases Prevention and Control reported 
an outbreak of urogenital schistosomiasis amongst a group of German tourists who had never 
visited a schistosome-endemic countries, in the French island of Corsica [17]. On further 
analysis, a large number of Bulinus truncatus snails were found along the shores of the river 
Cavu, which were infected with S.haematobium [17]. It was hypothesized that infected 
people had travelled from Senegal where this type of snail is abundantly present, to Corsica 
and in this way, the disease was spread [17].  The three primary species of the genus 
Schistosoma are Schistosoma mansoni, S. japonicum and S. haematobium. [4, 5, 8, 11, 12]. S. 
mansoni and S. japonicum are responsible for intestinal schistosomiasis, whereas S. 
haematobium causes urogenital schistosomiasis. Schistosomiasis is a prominent health 
concern in endemic regions and, unless detected early, can be responsible for high morbidity 
and mortality rates [9]. Of the three species, S. mansoni is most frequently maintained in 
laboratories in order to extensively study host-parasite interactions  [18]. 
Life Cycle of Schistosomes 
Schistosomes pass through two hosts in order to complete and maintain its life cycle: 
an intermediate snail host and a definitive mammalian host [3, 5, 13, 19]. Various freshwater 
snails can act as intermediate hosts for the different species of schistosomes [3, 6, 20]. These 
include Bioamphalaria glabrata and Bioamphalaria sudanica as hosts for S. mansoni, as 
well as Bulinus species as hosts for S. haematobium and Oncomelania species as hosts for S. 
japonicum. B. glabrata snails are common in South America such as Brazil and Venezuela, 
the Caribbean, Puerto Rico, Dominican Republic, Haiti, Guadeloupe and Suriname [18]. B. 
sudanica is more prevalent than B.glabrata in Africa, Madagascar and the Middle East [18].  
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After a person is infected with schistosomiasis, they release the parasitic eggs via 
feces or urine into water. The free-living, motile, non-feeding, non-reproducing and ciliated 
miracidia hatch from these eggs and they are attracted by a number of chemoattractants 
secreted by the intermediate snail host such as amino acids, magnesium ions, calcium, short-
chain fatty acids, sialic acid, ammonia, glutathione, inorganic ions, D-glucose and 
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glycoprotein [21]. The apical papilla of the miracidia facilitates its attachment to the snail, 
and the proteases are secreted from the apical and lateral glands. These secretions along with 
mechanical movement allows the miracidia to penetrate  the snail through the exposed head, 
foot, tentacle and mantle regions of the snail [3, 22-25]. Once inside the snail, the miracidia 
sheds its ciliated plates and a new syncytial tegument is formed. Asexual development of the 
larval stages of the parasite occurs within the intermediate snail host [22, 24, 26], producing 
two generations of multicellular sporocysts (the mother and the daughter), which finally 
differentiate into thousands of free swimming, infectious cercariae. Once mature, they are 
released from the birth pores of the daughter sporocysts into the fresh water triggered by  
sunlight [3, 20, 22-25]. 
However, certain specific populations of B. glabrata are resistant to transforming 
miracidia to sporocysts due to the presence of specific proteins like fibrinogen-related 
proteins (FREPs), B.glabrata snail granulin (BgGRN) and B.glabrata toll-like receptors 
(BgTLR), which activate the snail’s immune system, thus killing the miracidia, reducing or 
preventing the formation of infectious cercariae [18, 25]. 
The approximate length of a cercaria is 300-500 µm with the width being 
approximately 70 µm [27, 28], The body of the cercaria is covered by a sugar-rich 
glycocalyx, upon a layer of body membranes known as the tegument [24]. These parasites 
are free-living, highly mobile, non-feeding parasites, present in the upper layers of the water 
body and they possess a sole aim of locating a suitable mammalian host to infect by using 
their forked tail which allow them to propel through the water [20, 25, 28, 29]. Apart from 
humans, the S. mansoni cercaria can also infect rodents and non-human primates [4]. 
Cercariae have  two days (approximately 48 hours) to accomplish this feat and they rely 
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completely on glycogen stored in their bodies  especially in the tail [3, 23, 24, 29-32] The 
energy derived from the glycogen in the tail  fuels the movement, as well as use variety of 
ciliated sensory papillae located on the cercarial body [3, 23, 24, 29-32]. The stored glycogen 
undergoes a mechanism called glycogenolysis, where the enzyme glycogen phosphorylase 
converts glycogen to glucose-1-phosphate. Phosphoglucomutase acts on glucose -1-
phosphate producing glucose -6- phosphate, which then proceeds to glycolysis, to provide 
energy for the cercariae. If the parasites are unable to locate a mammalian host, the glycogen 
store is completely used up and the cercariae die, as they cannot perform glycolysis to sustain 
themselves.  
The human host is located through chemoattractants secreted by the human skin such 
as linoleic acid, ceramides and arginine. During infection, the cercaria penetrates the host 
skin by the mechanical activity of the tail as well as the secretion of proteolytic enzymes like 
proteinase, cercarial elastase and protease from the pre-acetabular cercarial glands, which 
allow the parasite to attach to and invade the mammalian skin [3, 13, 23, 24, 33-37]. The post 
acetabular glands secrete mucus for adhesion. During the invasive process, the cercariae shed 
their forked tails as well as the surface glycocalyx exposing the tegument underneath, thus 
transforming them into  schistosomules or somules  [3, 13, 23, 28, 29, 34, 36]. Along with 
the loss of the tail, the parasite also undergoes a change in physiology, which includes 
adapting to a different osmotic environment and a warm-blooded host [28, 29, 36]. 
The schistosomules remain on the host skin for a short period of time, after which 
they tunnel through the host’s dermis and travel through the circulatory system to the liver 
where they settle within the superior mesenteric venules that drain the large intestine 
gradually transforming into adult worms, capable of living up to 10 years in the body of the 
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host [8, 13, 14, 24, 35]. Schistosomes are dioecious by nature which means they develop 
either as male worm or as a female worm [6, 13, 24, 38]. Mature worms are approximately 7-
20 mm in length, with a cylindrical shape and they possess suckers, digestive tracts and 
reproductive organs [3]. The male worms are slightly shorter than the female worms, and 
they mate in the ventral gynaecophoric canal of the male worm [3-5, 8, 23]. After mating, the 
adult females produce a large quantity of eggs (approximately 100-300 eggs per day) 
utilizing energy from the  fatty acids from the human host by feeding on erythrocytes [4, 5, 8, 
39]. This energy is produced exclusively via anaerobic glycolysis  [3, 6]. Most of the eggs 
are excreted through the host’s urine and stool [8, 39] but many eggs become permanently 
lodged in the liver and the small intestine of the body [4, 39]. 
Schistosomiasis goes through two phases: acute schistosomiasis followed by chronic 
schistosomiasis. In acute schistosomiasis, some of the initial symptoms of the disease include 
dermatitis as a result of cercarial penetration into the skin, followed by Katayama fever 
which is characterized by an immunological response to the antigens present during the 
maturation of the schistosome worms; abdominal symptoms such as enlarged liver and 
spleen (splenomegaly), followed by pulmonary hypertension, which are caused by the 
somules migrating through the human body [4, 13, 23, 40, 41]. The chronic version of 
schistosomiasis is identified by the deposition of collagen and extracellular matrix (ECM) 
components surrounding the eggs in the liver which result in granulomas, simultaneously 
activating the host immune system by bringing CD4+ T cells, CD8+ T cells, B cells, M2 
macrophages, eosinophils and mast cells to the granulomatous inflammation [4, 13, 40, 42, 
43]. The pathology of the disease is primarily caused by the host’s immune response to the 
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accumulation of these schistosome eggs in the intestine and the liver, and not just by the 
juvenile or adult parasitic worms [4, 8, 13, 24, 40]. 
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1.2 Old and New Methods  For treating Schistosomiasis 
1.2.1. Oxamniquine  
Oxamniquine (OXAM), a tetrahydroquinolone compound, was developed by the 
pharmaceutical company Pfizer in the late 1960s and was sold under the brand name Vansil. 
It was introduced to the medical world in 1972 and was found to be effective only against S. 
mansoni schistosomules and adult worms (especially the adult male worms), and not against 
any other schistosome species.  
Once administered, (OXAM) is converted to a sulfate ester by a sulfotransferase 
enzyme, which then dissociates and binds to the parasitic worm DNA covalently [44-46]. 
The binding leads to disruption of the cell cycle and inhibition of protein synthesis, as a 
result of nucleic acid alkylation, causing paralysis in the affected worms [44, 45]. The 
paralyzed worms are transported from the mesenteric circulation to the liver of the host, 
where the cellular host response kills the parasite [44]. OXAM also promotes the damage of 
the tegument, thus exposing the antigens on the surface of the worms, which are identified by 
the host immune system  [4, 10, 44, 47, 48]. Another schistosomal drug called hycanthone 
was found to possess chemical and biological similarities with OXAM and its mechanism of 
action was caused by interfering with the synthesis of schistosomal nucleic acids. However, 
this drug also created the birth of hycanthone resistant schistosomes and was thus 
discontinued [49]. 
OXAM was used to treat approximately 10 million people in Brazil, however it led to 
resistance in the schistosomes, and thus had to be removed from the market in 2010 [45, 46]. 
It was found that a mutation in the enzyme of sulfotransferase made the drug ineffective [44, 
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45]. There were also reports of OXAM being responsible for seizures in epileptic patients 
and not being safe for pregnant women, hence the necessity to remove the drug quickly [4, 
10, 47, 48] 
1.2.2. Benzimidazole  
Benzimidazoles are broad spectrum anthelmintics and are used in cestode, nematode, 
protozoan, and microsporidia infections [50, 51]. The first of these drugs was tiabendazole 
introduced in 1961 [51]. The role of these drugs is to interfere with the assembly of 
microtubules, specifically binding to b-tubulin, causing the unfolding of the protein leading 
to a conformational change, which inhibits the polymerization of tubulin, a protein subunit of 
the microtubules [50, 51]. This, in turn has a cascade effect by restricting the role of tubulin 
in the movement of the subcellular components and metabolites within the cytoplasm leading 
to interfering in spindle formation during the process of cell division [50, 51]. When 
administered at a high concentration, it  converts fumarate to succinate, resulting in inhibition 
of microbial metabolism[51]. Triclabendazole (TCBZ) is a derivative of benzimidazoles and 
has been used to control o parasitic diseases such as Fasciola infections in veterinary medical 
sciences since the early 1980’s [52]. TCBZ has been used to kill adult S. mansoni worms 
causing parasitic muscular contraction, destruction of tegument, ultimately ending in 
parasitic death within 24 hours [50, 52] . However, severe side effects have been observed 
post treatment like abdominal pain, nausea, vomiting, weakness, liver enlargement [52]. 
Another derivative of benzimidazoles is flubendazole when administered to S. 
mansoni infected mice leading to significant changes in adult worm recovery, reducing the 
load of eggs and decreasing the formation of hepatic granulomas [50, 51]. Albendazole was 
developed in the early 1970’s and proved to be an effective broad spectrum antiparasitic 
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agent against nematodes, trematodes, cestodes, protozoan, ruminants and humans [51] 
However, this drug has been associated with teratogenicity and has been demonstrated to 
cause bone marrow toxicosis in dogs [51]. 
In order to survive in the human host, blood-feeding parasites such as S. mansoni and 
P. falciparum able to the bio crystallize of toxic heme molecules into inert and insoluble 
hemozoin (Hz), as evidenced by the presence of a significant quantity of Hz crystals obtained 
from the gut of the adult female S.mansoni worms [53]. Pyrido [1,2-a] benzimidazole 
derivatives (PBIs) possess both antimalarial as well as anti-schistosomal properties, examples 
of which are chloroquine (CQ), mefloquine (MQ) and quinine (QN ) [53]. All these drugs 
have demonstrated antischistosomal properties such as the inhibition of the formation of 
hemozoin crystals, thus exposing the parasites to the toxic effects of hemoglobin, killing the 
worms and decreasing egg deposition [53]. Benzimidazoles tend to pose a threat at high 
doses, by causing unwanted side effects in the host [51]. These drugs can also have the 
potential of having teratogenic properties [51]. 
1.2.3. Praziquantel  
Praziquantel (PZQ), which is sold under the brand name Biltricide and was 
introduced in 1978 [54],  is one of  the oldest and most popular drugs used to treat multiple 
parasitic worm infections, including schistosomiasis, related fluke infections such as liver 
and lung fluke infections caused by Fasciolopsis buski, various Echinostoma species, or 
Heterophyses herephyses, and also tape worm infections [3, 4, 55]. It can be used alone or in 
combination with corticosteroids and anticonvulsants [23]. PZQ is most effective against 
adult worms, but less effective against juvenile worms [4, 11, 54, 55]. The drug is used for 
mass administration (MDA) as it displays high efficiency and it is easy to administer, but 
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also due to the fact that it is well absorbed from the gastrointestinal tract [4, 6]. The exact 
molecular mechanism of PZQ is still unknown, however certain theories have been proposed 
to describe the drug’s mode of action [6, 54]. 
It is hypothesized that PZQ increases permeability of the parasitic membrane by 
binding to voltage operated calcium channels (VOCC), thus allowing a rapid influx of 
calcium ions [56]. This in turn, could result in the prolonged contraction of the worm somatic 
muscles leading to paralysis, and is accompanied with dramatic tegumental damage [6, 54, 
57]. The outer surface of adult S. mansoni worms is protected by a special double lipid 
bilayer tegument which plays an important role for parasitic survival and nutrition, signal 
transduction, osmoregulation, development, host-parasite interactions, by hiding surface 
proteins from the host immune system [14, 58, 59]. Damage to the tegument is believed to 
expose these very antigens, which are recognized by the host immune system and help to 
eliminate the injured worms from the body [6, 14, 57]. Another study states that PZQ is 
capable of disrupting the ion transport system, which could also lead to increased influx of 
calcium ions through the schistosomal cell membrane [3, 6, 57]. It has been also been 
suggested that PZQ causes the inhibition of nucleoside uptake and depletion of glutathione in 
S. mansoni worms [48, 60-62]. When glutathione is depleted from the parasite, it leads to an 
accumulation of glutaredoxin glutathione mixed disulfides in the cytoplasm, which in turn 
lead to the production of toxic reactive oxidative species (ROS), causing the death of the S. 
mansoni worms, thus making the thioredoxin glutathione reductase (which is replaced by 
SmTGR in schistosomes) an interesting potential drug target against schistosomiasis [48, 61-
64].  In fact, two earlier drugs, potassium antimonyl tartrate (PAT) and oltipraz (OPZ) were 
initially used as antischistosomal drugs around 1917,  and both have been discontinued since 
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then [61]. Although the exact mode of action of PAT and OPZ is not known, it was 
hypothesized that PAT stopped the action of the parasitic glycolytic enzyme, 
phosphofructokinase and OPZ inhibited the action of SmTGR, decreasing the glutathione 
levels and increasing ROS in adult worms  [61]. 
Recently, it has been established that the racemic structure of PZQ (R-PZQ) can act 
as a ligand that can bind and interact with the worm’s endogenous G protein coupled 
serotonin (5-HT)2B receptor in the human host [65]. In addition, R-PZQ may also be capable 
of selectively activating a human transient receptor potential metastatin type 8 channel 
(TRPM8) located on the plasma membrane, thus inducing extracellular calcium influx  [60].  
However, there are several problems associated with the usage of PZQ for schistosome 
control. PZQ never reaches 100% efficacy, and the drug does not prevent re-infection [66, 
67]. PZQ is not effective against juvenile worms and acts only on adult worms, which makes 
it a big limitation of the drug. Drug-resistant S. mansoni worms have been reported from 
various African countries including Egypt and Kenya [6, 11, 66]. In addition, PZQ tablets are 
large in size and bitter, and are therefore often crushed, added to juice for children  to 
consume [4]. Some of the common side effects of the drug include abdominal pain, 
headaches, dizziness and damage to the gastrointestinal (GI) tract with blood present in the 
stool [4, 60]. 
1.2.4. Artemether  
Artemisinins such as artemether and artesunate have been popular for their anti-
malarial properties since 1979 [52, 68]. Artemether  (ART), when used in combination with 
PZQ, has been found highly effective for anti-schistosomal treatment purposes, as it can 
target juvenile parasites better than PZQ [4, 6, 10, 23, 52, 61, 68]. Once the parasites are 
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exposed to ART and haemin, highly toxic free radicals are released in the guts of the worms, 
eventually killing them [68]. However, a major disadvantage of using ART for the control of 
schistosomiasis is the gradual widespread risk for the development of malarial parasite drug 
resistance especially for Plasmodium falciparum and/or P. vivax [6, 10, 23, 61]. 
1.2.5. Molluscides  
One of the earliest attempts to eradicate schistosomiasis was the use of broad spectrum 
molluscicides (e.g. niclosamide) for snail control, that would eliminate and kill the 
intermediate snail hosts; that procedure however was not successful in the long term since 
molluscides can be expensive, toxic and hard to maintain over a long term period [6, 11, 69]. 
1.2.6. Introducing Prawns as A Biological Mode of Control  
Other resources such as environmental modification, education and improvement of 
sanitation are being explored to help curb schistosome infections [11]. A biological method 
of reducing schistosomiasis has been proposed by releasing predators of snails like prawns 
into endemic regions [15, 16, 69]. In fact, snails infected with miracidia, were found to 
demonstrate slow movement and detectable physiological changes, making them more 
susceptible to predators, as compared to uninfected snails [15, 16, 69]. An example of such a 
fresh water prawn found in the water bodies throughout West Africa, known as 
Macrobrachium vollenhovenii, can feed on these host snails, thus causing a drastic reduction 
in the number of schistosomiasis cases [69]. However, the idea of introducing prawns to 
schistosome contaminated regions has not been widely applied, due to lack of native species, 
to keep the prawns under biological control, as well as risking the chance of causing 
unwanted environmental effects [69].  
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Table number 1.1. Table depicting the different drugs used to treat schistosomiasis, along 
with their targets, mode of action and the reasons for being discontinued. 
 
1.2.7. New Approaches Towards Drug Therapy 
With the epidemic of schistosomiasis spreading worldwide, it is of great importance 
that effective antischistosomal drugs are developed to combat the disease. In 2009, the  
genome of S.mansoni was sequenced, using whole genome shotgun sequencing and provided 
11,809 putative genes, encoding 13,197 transcripts, making schistosomes the first of the 
phylum Platyhelminthes to be completed sequenced [66]. The identified genes included those 
which produced proteins such as cadherins (for cell adhesion), Notch/Delta (for tissue 
development), histone acetyltransferases (for histone modification), tetraspanins (for 
structural proteins), fucosyl and xylosyltransferases (glycans expressed at the host-parasite 
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interaction), invadolysins (for host invasion), cathepsins (blood feeding), thioredoxin 
glutathione reductase (for anti-oxidant activities), metabolic enzymes (glycolysis, TCA cycle, 
pentose phosphate pathway), kinases, proteolytic enzymes etc [66]. 
From the genome sequence, 92 putative G-protein coupled receptors or GPCR 
encoding genes were identified which included members from the rhodopsin family, amine 
receptors, neuropeptides and hormone receptors [66]. In 2011, the first comprehensive 
genome wide study of platyhelminth GPCRs was first published by Dr. Mostafa Zamanian 
and Dr. Tim Day’s group at Iowa State University [70]. Other receptors identified were 
ligand gated ion channels, glutamate activated cation channels, ATP gated ion channels, 
nicotine acetylcholine receptors and voltage gated sodium, potassium and calcium channels  
[66]. Antischistosomal drugs which can bind to schistosomal receptors and channels which 
are capable of causing neuromuscular impairment are preferred targets for potential 
anthelminthic drugs [71]. Very recently, a paper published by the Marchant group at the 
University of Wisconsin-Madison, reported one such drug, nuciferine to be promising, the 
drug being an aporphine phytochemical found in the lotus plant [71]. It has been used in 
traditional medicine and is capable of blocking the serotonin or 5-hydroxytryptamine (5HT) 
receptor Sm5HTR, leading to a decrease in worm motility [71].  
Considerable research is being carried out for the production of anti-schistosomal 
vaccines, by evaluating specific schistosome molecules which are exposed to the immune 
system of the host, and are important for the survival of the parasites as they travel through 
the host circulatory system, absorb nutrients and avoiding the host defense system [11, 34]. 
These targets include S. mansoni fatty acid binding protein, tetraspanin, and S. haematobium 
glutathione S-transferase which has presently reached phase II of clinical trials [3, 11, 40]. 
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Other vaccine candidates include S.mansoni calpain, sodium/potassium ATPase, succinate 
dehydrogenase iron sulfur protein as well as S. japonicum associated with heat shock protein 
70 (HSP70) ; however further research is necessary to allow them to be eligible for  human 
trials [3, 11, 59]. Venom-allergen-like proteins (VALs) are abundant in many different 
helminth species, and have been used for trial runs to treat hookworm infections in humans, 
and could be considered as potential vaccine antigens to treat schistosomiasis [59].  
The isolation and detection of extracellular vesicles or EVs or exosome like vesicles 
(ELVs) secreted by adult S. mansoni worms are found to contain a number of proteins whose 
functions include intercellular communication; activating the immune system; metabolic 
proteins involved in glycolysis; metalloproteases and elastase to allow host penetration [14, 
37]. Some of the proteins which have been identified from parasitic ELVs such as ATP-
diphosphohydrolase1 (ATPDase1), Sm 22.6, and cathepsin B can prevent blood coagulation, 
and thus allow the worms to migrate easily through the bloodstream [37]. Proteins and 
infection related biomarkers were identified from schistosome ELVs may be designed as 
targets for potential anti-schistosome vaccines [14, 72].  
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1.3. The Importance of Schistosomal Cercarial Motility in The Spread of 
Schistosomiasis 
The non-feeding, short-lived and free-swimming S. mansoni cercaria is the most infectious 
stage of the life cycle of schistosomes, which bridges the gap between the intermediate snail 
and the mammalian definitive host [28, 73]. The motility of the cercariae is responsible for 
the spread of schistosomiasis to humans and thus the identification of the molecules 
responsible for the mechanism behind the motility of the cercarial tail, can be promising 
targets for the design of chemotherapeutic drugs.  
1.3.1. The Role of The Muscular Organization of The Parasite on Cercarial Motility 
Cercarial motility is largely dependent on the activity of the tail. The muscles in the 
furcae allow the cercariae to switch from backward to forward swimming and the swimming 
behavior has been broadly classified into three main categories (1) a tail-first mode where the 
cercarial tail fork is fully extended and the cercariae moves against gravity  (2) a free-sinking 
method where the fork is partially extended and the cercariae is negatively buoyant and 
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lastly, (3) a head-first method where the cercarial tail fork is folded back, critical to host 
penetration [27, 30].  
 
 
The anatomy of the cercarial muscle tissues was studied using fluorescent 
microscopy, along with histological stains such as fluorescein isothiocyanate (FITC) labelled 
phalloidin which labels filamentous actin [24, 27]. The main body of the cercariae is made up 
of diagonal muscle fibers, longitudinal muscle fibers and circular muscle fibers [27]. The tail 
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is broadly divided into two main components: the upper portion, which is made up of striated 
tail muscles, and the lower bifurcated forked tail or furcae, which are composed of circular 
muscle fibers and longitudinal muscle fibers [24, 27, 28]. The motility of the cercarial tails 
depends on both thick and thin myofilaments, and they derive their energy from adenosine 
triphosphate (ATP) which is produced in abundance from mitochondrial cells [28]. The 
stored glycogen in the cercariae is converted to glucose-6-phosphate through glycogenolysis, 
which is then converted to glucose by the process of glycolysis, which is further transformed 
to energy in the form of adenosine triphosphate (ATP) using the Kreb’s cycle [31, 32, 36]. 
1.3.2. The Role of Chemical Factors on Cercarial Motility 
On exposure to light, the positively phototropic cercariae are shed from the infected 
B. glabrata snails and they accumulate along the surface of the water, where they can easily 
come in contact with humans or other mammalian hosts [74]. Free fatty acids (linoleic acids) 
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act as chemical signals which attract the cercariae to the skin of humans [74]. To assist in the 
invasion process, the cercariae uses its acetabular glands which are made up of four pre-
acetabular glands and six post acetabular glands, located on the ventral part of the cercarial 
body [34]. The glands secrete mucous and proteolytic enzymes [24, 27, 28, 34, 74] which 
assist in host tissue invasion, breakdown of tissue barriers, and migration through the host 
body [24, 73, 74]. Once inside the  mammalian skin, the tail is detached from the rest of the 
body and the schistosomule continues its journey through the host body [24, 28, 34, 74].  
1.4 The Role of Neuropeptides and Neurotransmitters in Schistosomal Motility 
Schistosomes are dependent on their neuromuscular system for a whole range of 
functions such as locomotion, penetration of cercariae through the human skin, migration of 
schistosomules through the circulatory systems, controlling the muscles of the suckers, 
reproductive, digestive, excretory systems and coupling of adult worms [75, 76]. Classical 
neurotransmitters and neuropeptides are key components in the regulation of the 
neuromuscular system of helminths [75]. The movement of the juvenile worms is dependent 
on the coordinated contraction of the longitudinal muscles and the elongation by the circular 
muscles [77]. Neurotransmitter receptors and neuronal proteins associated with the central 
nervous system (CNS) and the peripheral nervous system (PNS) have always been 
considered as potential targets for chemotherapeutic agents [21, 76].  
1.4.1. Neuropeptides  
With the availability of whole genome data, bioinformatic screens such as web-based 
basic local alignment search tool (BLAST), scientists have identified a plethora of putative 
amidated and non-amidated neuropeptide encoding genes in schistosomes and related 
platyhelminths [66, 78, 79]. The nuclear genome of S. mansoni was sequenced in 2009, 
 
22 
encoding 11,809 putative genes [66]. Schistosomes possess well-developed families of 
neuropeptides which consist of neuropeptide F (NPF) like peptides and myoexcitatory 
FMRFamide-like neuropeptides (FLPs), which have been identified and studied in whole 
worms, muscular strips and isolated individual muscular fibers of various flatworm species 
[76, 80, 81]. Schistosomal NPFs are polypeptides are prevalent platyhelminthes, however 
they are absent from the human genome, thus making NPF an attractive anthelmintic drug 
target [35, 66]. The genome of S. mansoni revealed the presence of NPP-21a and NPP-21b, 
concluding that NPFs and NPYs possess a common ancestry [66]. Eighteen distinct amidated 
peptides have been identified in the CNS and the PNS of S. mansoni, some of which have 
myoexcitatory functions, locomotion, reproduction and spread of infection [66, 78, 79]. This 
includes the S. mansoni neuropeptide precursor gene (Sm-npp-1) which is expressed in both 
larval and adult parasitic worms and encodes the myoexcitatory GFVRIamide. Classical 
neurotransmitters capable of affecting worm motility include serotonin (5HT), dopamine, 
histamine, glutamate and acetylcholine [35, 75, 82]. YIRF-amide and other similar peptides 
are potently myoexcitatory on S. mansoni dispersed muscle fibers [79]. Sm-NPP-1 
(GFVRIamide) and Sm-NPP-5 (AAYMDLPWamide) were found in the schistosomal 
nervous system thus proving to be promising targets for future chemotherapeutic research 
[79].  
1.4.2. Serotonin (5HT) 
Like PZQ, 5HT has a myoexcitatory effect on whole worms, but the overall responses 
of both molecules are significantly different from each other [54, 65]. 5HT is an important 
myoexcitatory neurotransmitter for schistosomes, as it stimulates motility and controls the 
contraction of the muscles [77, 83]. 5HT also plays roles in larval growth, development and 
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maturation [75]. Muscle fibers isolated from adult S. mansoni worms proved the effect of 
5HT on the contractility of the muscle fibers  [82, 84].  The receptor for 5HT or Sm5HTR  
was the first to be identified as a functional serotonin receptor and is widely expressed in the 
nervous system of both juvenile and adult worms, [77]. The ligand 5HT when bound to the 
5HT receptor, stimulates adenylate cyclase by activating the Gs (stimulatory) subunit of the 
trimeric G-proteins, thus increasing the concentration of cAMP, which releases calcium from 
intercellular storages such as the endoplasmic reticulum [77, 82]. Other functions of 
Sm5HTR include the uptake of glucose, glycogen utilization and carbohydrate metabolism, 
thus providing energy for muscular contraction [75, 82, 85].  
The role of Sm5HTR in parasitic schistosomule and adult worm motility was 
confirmed by RNA interference (RNAi) [71, 77, 83]. When compared to untreated controls, 
the Sm5HTR dsRNA treated schistosomules were unable to elongate their bodies, and thus 
movement was affected resulting in hypomobility, thus identifying that GPCRs like 
Sm5HTR can be potential anthelmintic drug targets [71, 77, 83]. Nuciferine, D-glaucine and 
boldine are aporphines or tetracyclic alkaloids, are capable of blocking Sm5HTR, thus 
affecting schistosomal motility [71].  
1.4.3. Dopamine and Histamine  
Apart from 5HT, dopamine and histamine are the other two biogenic amine signaling 
neurotransmitters [75, 76, 81]. The rhodopsin-like GPCRs for the dopamine receptors are 
expressed in the parasitic musculature whereas the receptor for histamine is found in the 
tegument of the schistosomules [35, 75, 81]. Biogenic amines are also responsible for 
stimulating specific proteins such as activated protein kinase A (PKA), the functions of 
which include of  activation of transcription factors, metabolic enzymes, signaling proteins, 
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neuromuscular communication, survival, muscular activity and can be stimulated by biogenic 
amines such as 5HT and dopamine, present in the nervous system of the worms [35].  
1.4.4. Glutamate 
Glutamate is a myoexcitatory amino acid classical neurotransmitter, responsible for 
the stimulation of isolated muscle contraction, interneuronal signaling within the central 
nervous system (CNS) and the control of egg production in female worms [75, 76]. The 
biochemical receptors for glutamate fall into one of four main categories: a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPA receptors), N-methyl-D-
aspartate receptors (NMDA receptor), metabotropic glutamate receptors and the less 
abundantly distributed kainite receptors.  
1.4.5. Acetylcholine 
Acetylcholine or ACh is a well-known excitatory neurotransmitter present in the 
neuromuscular junction of the nervous system of many types of animals and humans. In both 
vertebrates and invertebrates, ACh controls important functions of the body in both the 
central and the peripheral nervous systems, such as muscular contraction, secretion from the 
glands, memory formation and learning [86, 87]. The presence and role of this 
neurotransmitter in S.mansoni was first reported in the early 1950’s and it was observed that 
the concentration of ACh in S.mansoni was similar to that present in the grey matter of 
human brain cortex [88]. However, the role of ACh in schistosomes is inhibitory, rather than 
excitatory, causing muscular relaxation leading to paralysis [86-88]. There are two main 
groups of ACh receptors: –ionotropic nicotinic receptors which are  ligand-gated ion 
channels permeable to sodium, potassium and calcium ions; and metabotropic muscarinic 
receptors, which belong to the G-protein coupled receptors (GPCR) family [86, 87].  
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Nematode ligand gated nicotinic receptors have been previously used as targets for 
the manufacture of antiparasitic drugs [86]. A paper published in 2014 by Dr. Paula Ribeiro’s 
group explored the nicotinic acetylcholine receptor (nAChR) to confirm the inhibitory role of 
these receptors in the S.mansoni motility [87, 89]. Using computational biology, it was 
discovered that 5 of the schistosome nAChR subunits were acetylcholine gated chloride 
channels  (Sm ACC) located in the peripheral nervous system of the schistosomes [87]. 
Using RNAi, it was confirmed that SmACC activation was caused by an influx of chloride 
ions, which was responsible for the inhibitory response observed in schistosomes [87]. Based 
on this analysis, acetylcholine-gated chloride channels present a promising target for future 
antischistosomal drugs.  
Muscarinic ACh receptors (mAChRs) are structurally within the Rhodopsin GPCR 
family. Invertebrates feature a closely-related family to as G-protein coupled acetylcholine 
receptors (GARs) [86]. GARs are related to, but distinct from mAChRs. The very first 
complete functional analysis of schistosomal GAR (SmGAR) was published in 2015 by Dr. 
Paula Ribeiro’s group and it was demonstrated that by knocking down SmGAR, there was a 
significant reduction in schistosomal larval motility, suggesting the role of these receptors in 
the migratory process of S. mansoni [86].  
An important question was raised regarding the role of these receptors—since ACh 
has an inhibitory effect on the schistosomes, knocking the SmGAR would hypothetically 
increase the movement of the somules, however the opposite effect was noticed [88]. It was 
suggested that a number of receptors stimulated all at once were responsible for the reduction 
in parasitic motility, and also there is a possibility of some of the receptors possessing a 
stimulatory effect on the schistosomes [86].  
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1.5 Microfluidics as A Novel Platform to Study Schistosomal Motility 
Microfluidic systems are increasingly gaining a lot of attention due to the fact that 
they are designed to analyze the behavior and movement of organisms as they move through 
manipulated and controlled fluid flowing through the microchannels of the platform. The 
benefits of using such a device include the ease of manufacturing the device, small size of the 
chip, the use of less sample volume, thus not wasting excess sample, saving in chemicals, the 
ease of portability, conducting a number of experiments simultaneously on the same 
platform, improved sensitivity and increased resolution [90-92]. These chips have been used 
for screening anthelmintic drugs on free living and parasitic nematodes  [91, 93]Using this 
approach, we studied and analyzed the movement of S. mansoni schistosomules in custom 
made microfluidic platforms with sinusoidal microchannels, produced using biologically 
inert, transparent and gas permeable polydimethylsiloxane (PDMS) on a glass slide, by 
standard lithography technique. This experiment was conducted in collaboration with the 
micro/nano laboratory of the Electrical and Computer Engineering Department of Iowa State 
University, who provided the microfluidic channels for our experiments. The goal of this 
research project was to establish a new screening platform where the microchannels 
mimicked human blood vessels, in order to test the effect of various agents on 
schistosomules, as they migrate through the body of the host.  
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1.6 The Proteomic Analysis and The Identification of S. mansoni Cercarial Proteins 
The free-swimming, very motile and highly infectious cercarial forms of S. mansoni 
are responsible for bridging the gap between the invertebrate snail host and the human host, 
resulting in schistosomiasis. The proteins present in the cercarial tail are responsible for 
keeping the cercariae alive in the fresh water, to seek and penetrate a host. However, the 
proteins behind these functions are poorly understood. Functional proteomics, the large scale 
characterization of proteins in a biological sample, has gained importance in recent years, as 
it helps to identify a large number of interesting proteins as well as their functions, locations, 
modifications in a single sample simultaneously [22, 94]. Proteomic analysis of the material 
secreted by the cercariae post infection, have identified a carbohydrate rich glycocalyx, 
which would normally activate the host immune system, but is discarded once the cercariae 
invades the host [95]. Other identified proteins from the cercarial secretions include the 
proteolytic enzymes released by the acetabular glands, which helps the parasite to tunnel 
through the epidermis and enter the host circulatory system [95]. An analysis of the 
miracidium proteome revealed the presence of proteases, venom allergen like proteins 
(VALs), heat shock proteins, all of which function in the survival and development of the 
miracidia in the intermediate snail host [22].  
Using mass spectrometry and proteomic analysis, we have attempted to present a 
complete analysis of the cercarial tail proteome, and a thorough comparison between the 
proteins located in the cercarial body and those present in the cercarial tail. By identifying 
novel proteins in the cercarial tail, we aim to identify possible drug targets, which can 
intervene and prevent host invasion. 
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1.7  Organization of The Dissertation 
For my doctoral thesis, I have used two  novel molecular techniques to study the 
motility of S. mansoni cercaria and S. mansoni schistosomules—microfluidics to improve 
motility platforms to study the movement of somules, and a thorough proteomic analysis of 
the cercarial proteins which may be responsible for the parasitic movement . To my 
knowledge, these techniques have not been tested before and we hope to use parasitic 
motility as a focus of future research studies, to combat the spread of schistosomiasis.  
1.7.1. Objective Number 1 
The first part of my thesis is based on the design and use of microfluidic devices to 
analyze parasitic movement [92]. Microfluidic assays with microchannels have been used 
previously to study the movement of C.elegans, in response to various drugs [91].  
Specifically, we have implemented a novel lab-on-a-chip approach to study schistosomule 
motility in an environment more akin to that of the host’s circulatory system. Our aim for this 
project was to improve motility platforms for the study of schistosomal movement, which 
would potentially assist scientists in tracking the parasitic movement, under the effect of 
drug. 
1.7.2. Objective Number 2 
The integration of novel techniques such as proteomics, functional genomics, and 
computational biology, have allowed scientists and researchers to make significant advances 
in the scientific world.  For the second part of my doctoral thesis, we have extracted and 
analyzed the proteome of cercarial tails, which plays an essential role in the spread of the 
disease. Our goal for this project was to identify and compare the functions of the proteins in 
the cercarial bodies with those present in the cercarial tails, using mass-spectrometry to map 
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separate body and tail proteomes. Our analysis has confirmed the presence of 791 proteins in 
the cercarial tail as compared to 645 proteins in the cercarial body. Using this information, 
we have chosen specific cercarial tail proteins, not present in the body, which could be 
potentially used as potential targets for future drug research. By preventing the transport of 
the cercariae from the snail host to the mammalian host, we hope to reduce the spread of 
schistosomiasis.  
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CHAPTER 2. USING MICROFLUIDIC ASSAYS TO STUDY THE MOTILITY OF 
SCHISTOSOMA MANSONI SOMULES 
 
Modified from a paper to be submitted in PLoS Pathogens 
Sreemoyee Acharya1,3,4, Zach J. Njus2,4, Prince N. Agbedanu2, Santosh Pandey2,4, Gunnar R. 
Mair1, Tim A. Day1,4 
2.1 Abstract 
Schistosomiasis or Bilharzia is the second most important neglected tropical disease 
(NTD), after malaria, and is caused by parasitic helminth trematodes called Schistosomes, 
which belong to the phylum Platyhelminthes. According to a report filed by the World 
Health Organization (WHO) in 2016, schistosomiasis is responsible for approximately 
200,000 deaths per year in sub-Saharan Africa alone. Praziquantel is the lone anthelmintic 
drug used to treat the disease, however in recent times, there is an urgent need for better and 
more efficient drugs to combat the disease. Although the life cycle of the causative agent of 
intestinal schistosomiasis, Schistosoma mansoni through the intermediate snail host and the 
definitive human host is well known, the navigation and kinetics of the movement of the post 
infection juvenile worms through the convoluted pulmonary and blood vessels in the human 
host  remain largely unexplored. The study of schistosomal movement through the host has 
been hindered by the complex life cycle,   high expense, poorly designed motility assays  and 
the lack of high thorough put screening methods. In this paper, we have attempted to study 
the movement of S. mansoni somules through unique custom manufactured microfluidic 
chips with sinusoidal microchannels produced from polydimethylsiloxane (PDMS), so that 
the channels could provide a route similar to the human circulatory system. These 
microfluidic platforms have been used previously to analyze the movement of C.elegans 
successfully. The movement of the somules through the microchannels was recorded, and 
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these recordings were analyzed using a custom-made software. The goal of this research  
paper is to establish a novel and robust experimental device for screening potential anti-
schistosomal compounds, and improving the definition of such motility assays, allowing 
researchers to distinguish between contractile activity and directional movement of 
organisms. 
1 Department of Biomedical Sciences, Iowa State University, Ames, IA, USA 
2 Department of Electrical and Computer Engineering, Iowa State University, Ames, IA, USA 
3 Primary authors 
4 Author for correspondence 
2.2. Introduction 
2.2.1. Life Cycle of Schistosomes 
Neglected Tropical Diseases (NTDs) are a diverse group of highly infectious diseases 
that are mostly prevalent in tropical and subtropical countries [4]. The Centers for Disease 
Control and Prevention (CDC) reported that almost one billion people, mostly from low-
income and middle-income populations, are affected by NTDs, in at least 149 countries. 
Schistosomiasis or Bilharzia is the second most important NTD, after malaria, and is caused 
by blood dwelling parasitic helminth trematodes called Schistosomes [4, 96]. These parasitic 
organisms belong to the phylum platyhelminthes and are responsible for infecting more than 
200 million people worldwide [4, 12, 33, 96]. According to a report filed by the World 
Health Organization (WHO) in 2016, schistosomiasis is responsible for approximately 
200,000 deaths per year in sub-Saharan Africa alone.  The three important species of the 
genus Schistosomes are Schistosoma mansoni, Schistosoma japonicum and Schistosoma 
haematobium, of which the life cycle of S.mansoni is more frequently maintained in 
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laboratories for research purposes [12, 96]. S. mansoni and S. japonicum are responsible for 
intestinal schistosomiasis, whereas S. haematobium is responsible for urogenital 
schistosomiasis [4, 12, 96].  
The life cycle of S.mansoni is complex as it needs to pass through two hosts—the first 
one being an intermediate invertebrate snail host and the second being a definitive vertebrate 
mammalian host [4, 33, 96]. When people are infected with schistosomiasis, they shed the 
parasitic eggs through their urine and/or feces into freshwater, where the eggs hatch to 
release free-living, non-feeding, highly motile ciliated miracidia [4, 33, 96, 97]. The 
miracidia then proceeds to infect an intermediate snail, Bioamphalaria glabrata in the case of 
S.mansoni, in which it undergoes asexual reproduction to produce a large number of 
sporocysts [4, 33, 96, 97]. The sporocysts mature in order to develop into tens of thousands 
of  highly infectious and extremely motile cercariae, which are released into the water to 
locate a mammalian host [4, 33, 96]. The cercariae proceeds to invade the host skin by 
tunneling through the dermis, using both the mechanical force of its bifurcated tail as well as 
the proteolytic enzymes secreted from the cercarial acetabular glands [4, 33, 96, 98]. The 
extremely infectious cercariae is responsible for spreading schistosomiasis as it bridges the 
gap between the snail vector and the human host. Once inside the skin of the mammalian 
host, the cercariae discards its tail and transforms into schistosomules, which then travel first 
through the host circulatory system to the lungs, and then via the systemic circulation to the 
portal veins [33, 96, 97, 99]. Within the superior mesenteric veins, the dioecious parasites 
mature into either male adult worms or female adult worms, which mate, producing 100-300 
eggs per day - some of which are excreted and most of which are accumulated within the 
host tissues and organs, leading to the pathogenesis of the disease [4, 8, 12, 33, 96, 99]. The 
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pathology of schistosomiasis is caused primarily by the host’s immune response to the 
accumulation of schistosome eggs in the intestine and the liver, and not just by the presence 
of juvenile and adult parasitic worms [4, 8, 13, 97]. 
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2.2.2. Importance Of Schistosomal Motility In Spreading Schistosomiasis 
Although the life cycle of the adult S. mansoni worms within the mammalian host is 
well understood, the navigation and the kinetics of the movement of the somules through the 
convoluted pulmonary and blood vessels remain largely unexplored. According to early 
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studies conducted using compressed tissue autoradiography, the migration of the somules 
through the pulmonary capillaries demonstrated a rather strenuous, protracted and slow 
process as the parasites squeeze through the tight walls of the of the blood vessels [33, 97, 
99-101].  Schistosomes promote vasodilation of the blood vessels by generating specific 
metabolites such as kinins (bradykinins), biogenic amines (histamine and serotonin), 
ecoisanoids, and nitric oxide to allow the worms to travel freely [102]. 
The movement of somules through the body depends on a number of chemical and 
biological factors [99, 102]. Proteolytic enzymes like proteases, caspases and elastases 
secreted from the cercarial acetabular glands, assist in parasitic movement through the 
capillaries [33, 100]. Schistosomules are also guided by blood serum containing L-arginine 
and glucose as signaling molecules [98]. The tegument on the surface of the somules shields 
the worm antigens from being recognized and attacked by the host’s immune system [33]. In 
order to survive, schistosomes can crystallize toxic heme molecules from human erythrocytes 
into insoluble hemozoin molecules (Hz), which allow the parasite to move  through the blood 
vessels without any obstruction [53].  
Once the somules reach the liver, they start to feed on blood cells, which provide energy in 
the form of adenosine triphosphate (ATP) for further migration and maturation [33, 101]. 
The maintenance of the S. mansoni life cycle and the spread of schistosomiasis depends on 
the migration of the somules through the body of the host as well as successful evasion of the 
immune system. 
2.2.3. Neuromuscular Organization of Schistosomes. 
Schistosomule motility depends upon a rhythmic pattern of alternating cycles of 
elongation and contraction of the body [103]. Central to the motility of the parasites is the 
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schistosome neuromuscular system, which is responsible for controlling the functions of its 
muscles [77, 103]. Confocal scanning laser microscopy of fluorescein isothiocyanate (FITC) 
labelled phalloidin staining of cercarial actin filaments, was used to demonstrate the detailed 
organization of the muscular system [27, 104]. The cercarial body is composed of diagonal 
muscles, longitudinal muscles and circular muscles which are responsible for locomotion 
[27, 104]. The tail is made up of two parts—the anterior portion is composed of striated tail 
muscles, and the posterior bifurcated forked tail or furcae, is composed of circular muscles 
and longitudinal muscles [27, 104]. The alimentary tract and the reproductive system of the 
parasite is made up of outer circular muscles and inner longitudinal muscles [105]. Once the 
cercariae invade the human host, they discard their tails and transform into schistosomules, 
which then continue on their journey. The mobility of the somules is dependent on the 
coordinated contraction of the longitudinal muscles and elongation of the circular muscles of 
the body [77]. Since the neuromuscular system plays a significant role in the maintenance 
and the survival of the parasites, this system is often the focus for potential anti-schistosomal 
drugs targets.   
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2.2.4. Helminth Neuropeptides 
Neuropeptides (NPs) are the primary neuromediators of the members of the 
platyhelminth family and the nematode family [106, 107]. NPs are small protein-like 
molecules, which are secreted and used by neuronal cells for interneuronal communication. 
Using a Basic Local Alignment Search Tool (BLAST) server on the NCBI website 
(http://www.ncbi.nlm.nih.gov/BLAST), more than 100 helminth neuropeptides have been 
identified in both platyhelminths and nematodes [79, 80, 108]. In platyhelminths, there are 
two families of NPs, FMRF-amide like peptides (FLPs) / FMRF-amide related peptides 
(FaRPs) and Neuropeptide F (NPFs) [106, 107, 109, 110].  
FLPs or FaRPs are short peptides which are composed of 4-6 amino acids and are 
particularly abundant in nematodes with potentially myoexcitatory properties [106, 109-114]. 
In 1994, FLPs were demonstrated to inflict myoexcitatory effect on S. mansoni isolated 
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muscle fibers.  Classical neurotransmitters and NPs are key components for regulating and 
coordinating the helminth neuromuscular system [75, 109, 114]. In 2007 the very first 
platyhelminth NP receptor was identified in Giardia tigrina and named GtNPR-1 (G.tigrina 
neuropeptide receptor-1)  [106, 112]. It was demonstrated that GtNPR-1 was primarily 
responsible for neuromuscular excitation in platyhelminths, and the mode of action was via a 
G-protein coupled receptor (GPCR) pathway [106, 109, 112, 113]. NPs such as YIRF-amide, 
GYIRF-amide and RYIRF-amide were found to induce high levels of muscular contraction 
in parasitic flatworms, with GYIRF-amide being the most potent one amongst the three [105, 
106, 108, 112, 114, 115]. However, McVeigh et al. in 2011, demonstrated that when YIRF-
amide was applied to schistosomes, the parasites exhibited inhibition, which was contrary to 
the results derived by Day et al. in 1997 [80]. It was assumed that the reduction in motility 
was due to muscular paralysis caused by spastic (excitatory) or flaccid (muscular relaxation) 
[80]. When GtNPR-1 was screened against 220 neuropeptides it was found that three 
nematode FLPs, encoded by the flp-1 gene, AAADPNFLRF-amide, SDPNFLRF-amide and 
SADPNFLRF-amide, were found to be more potent than GYIRF-amide, but since they were 
nematode FLPs, they could not be tested on helminths [106, 111, 112].  
On the other hand, NPFs have 36-39 amino acids, making them longer in length than 
FLPs, and they possess GRPRF-amide (Gly-Arg-Pro-Arg-Phe)-amide at their carboxy ends 
[106, 107, 112]. A paper published in 2004 first identified the presence of NPF from 
S.mansoni and S.japonicum and it was demonstrated that that the NPF family  caused a 
reduction in the cAMP concentrations, and had an inhibitory effect on the neuromuscular 
anatomy of the parasites [107]. In 2009 the genome of S. mansoni was first sequenced and 
was found to encode 11,809 genes with thirteen putative neuropeptides [66]. Since NPFs are 
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most abundantly distributed in parasites, they are considered potential targets for future 
anthelmintic drug therapy [107, 110, 112]. 
In 2011, a new family of helminth NPs was identified in both platyhelminths and 
nematodes, one of which was found to be expressed in both S.mansoni somules and adult 
worms-the NP precursor gene Sm-npp-1 which codes for GFVRI-amide and AFVRL-amide 
[80]. Using molecular techniques like immunocytochemistry (ICC) and confocal microscopy, 
GFVRI amide was found to be located in the neurons of the cerebral ganglion of S. mansoni 
and  not detectable in somatic muscles or organs [80, 110]. These peptides demonstrated an 
inhibitory effect on both adult worms and somules, however when Sm-npp-1 was knocked 
out using RNAi, no phenotypic change in motility or morphology was observed [80]. 
Along with S.mansoni adult worms and somules, AFVRL-amide was also identified as one 
of the NPs in annelid worms, Eisenia fetida, using affinity chromatography combined with 
LC-MS/MS techniques [116]. However, the role of AFVRL-amide is not completely 
understood.  
Parasitic helminth trematode members of the platyhelminth phylum such as 
schistosomes are completely dependent on their neuromuscular systems for the regulation of 
their activities such as locomotion, migration of somules through the host circulatory system, 
evading the host immune system, controlling the muscles of the suckers, reproduction, 
digestion, excretion and ultimately the maturation of somules to adult worms [75, 76, 106]. 
The examination of isolated muscle fibers from S.mansoni worms identified two types of 
major excitatory neurotransmitters: FaRPs/FLPs  and serotonin (5-HT) [84, 105, 108, 115]. 
FaRPs/FLPs were denoted as the primary neurotransmitter on S. mansoni muscles 
responsible for neuromuscular activity [114, 115].  
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Myoexcitatory 5-HT is  abundantly expressed throughout the central and peripheral nervous 
systems of the schistosomal body and it assists in increasing motility, sucker function and 
reproduction by acting on its muscle fibers, in a more modulatory role [77, 108, 117]. 5-HT 
signals through one of the few characterized G protein coupled receptors (GPCRs), which, 
when suppressed by RNA interference (RNAi), results in reduced motility as well as 
demonstrated resistance towards exogenous treatment of 5-HT [77]. RNAi suppressed worms 
were observed to appear round in shape and unable to elongate their bodies, thus proving that 
5-HT has a very important role in maintaining the neuromuscular system of schistosomes 
[77]. 
2.2.5. Motility Assays 
Screening techniques such as enzymatic, colorimetric and fluorescence assays have 
been tested to evaluate whole worm motility [118]. In a paper published in 2015, an assay 
called the xCELLigence worm real-time motility assay or xWORM (ACEA Biosciences, San 
Diego, CA) was used to monitor the movement of different life cycle stages of S. mansoni 
[118]. The study of parasitic movement has been hindered by  expense, laborious nature and 
the lack of high thorough put screening methods, which is why it is necessary to develop a 
more affordable, easy and efficient way to analyze movement, in order to design anthelmintic 
drugs [118]. 
2.2.6. Microfluidic Assays 
Microfluidic systems are designed to analyze the behavior, manipulation and control 
of fluids, which are transported via capillary forces, with practical applications in 
biotechnology. The system has gained a lot of attention as a novel and controllable 
technology for carrying out experiments at the small scale like high thorough put drug 
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screening [119]. Most microfluidic analysis devices are simply miniaturized versions of 
macroscale systems [92]. The development of a miniature biological or chemical analysis 
device, popularly known as “lab-on-a chip”, started from the field of MEMS (Micro-electro-
mechanical systems) research [90]. Some of the advantages of microfluidic systems include 
the small size of the chip, the ability to work with small sample volumes, thereby saving on 
the cost of reagents and chemicals, but also allowing the development of highly sensitive 
devices [90]. Above all, microfluidic chips open up the possibility to conduct multiple 
experiments in parallel on the same chip with improved sensitivity, which facilitates the 
observation and the characterization of phenotypic characteristics in biological systems as 
well as correlate the change in motility associated with resistance [91]. These devices have 
been used for single cell handling, single cell culturing, microfluidic flow cytometry, cell 
sorters and macromolecular detection, as well as separation [33]. Multiparameter 
microfluidic bioassays with microchannels, created by lithography, have been utilized to 
research the movement of nematodes, C. elegans in particular, in response to various drugs 
[91].  Such experiments are typically recorded using video tracking, and with the help of 
specific tracking software, the changes in the kinetics of the worm’s locomotion is calculated 
[12]. 
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In order to mimic the movement of Schistosoma mansoni schistosomules through 
convoluted blood vessels, we have used a unique microfluidic platform with sinusoidal 
microchannels produced from polydimethylsiloxane (PDMS) by a standard soft lithography 
technique [93, 120]. This platform has been previously used to study the movement of C. 
elegans successfully [35, 36]. The strong, irreversible bond between PDMS and standard 
glass slides prevents leakage, making PDMS an ideal chemical to use for manufacturing 
microchips [119]. PDMS provides large range of advantages over other chemicals including 
optical transparency, gas permeability, non-toxicity, inertness and compatibility with aqueous 
solutions, thus making it suitable for microscopic observations [119].  
In this study, S. mansoni somule movement through such microchannels was 
evaluated and recorded, and these recordings were analyzed using a custom-made software. 
The aim of this paper is to establish a novel and robust experimental device for screening 
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potential anti-schistosomal compounds, and improving the definition of such motility assays, 
allowing researchers to distinguish between contractile activity and directional movement of 
organisms. 
2.3 Materials and Methods 
2.3.1. Experimental Animals 
The NIAID Schistosomiasis Resource Center of the Biomedical Research Institute 
(BRI, Rockville, MD) provided the S. mansoni infected Biomphalaria glabrata snails, 
through NIH-NIAID Contract HHSN272201000005I for distribution through BEI Resources. 
The infected snails were fed fresh lettuce leaves and maintained at 26°C-28°C in charcoal-
filtered, aerated water. 
2.3.2. Cercarial Shedding of Snails 
In a 250 ml. glass beaker containing 40 ml. of charcoal-filtered, aerated water, 
approximately 30-40 S. mansoni infected B. glabrata snails were placed. The water was 
enough to cover the snails. The cercariae were shed from the snails, by exposing the snails to 
a 120V 60W light bulb for up to 2 hours. The water from each beaker was filtered through a 
glass funnel (VWR catalog number #89428-960) containing a 47-uM pore sized metal screen 
(VWR catalog number # 89428-966). Once the cercariae were transferred to a pre-chilled 50 
ml. falcon tube placed on ice, the cercariae were allowed to settle at the bottom of the falcon 
tube. The supernatant was discarded, and 5-10 ml. solution with the pellet was left at the 
bottom of the tube.  
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2.3.3. Transformation Of Cercariae To Schistosomules, Separation And Collection Of 
The Somules 
In order to produce schistosomules the cercarial solution was vortexed 6-7 times for 1 
minute followed by 1 minute on ice thus manually separating the tails from the cercarial 
bodies. Percoll density gradient centrifugation was then used to separate the tails from the 
cercarial bodies.  40 ml. of a 60% Percoll solution were prepared from 24 ml. percoll (Fisher 
Scientific catalog number # 45001754), 4 ml. of 10X MEM Vitamin solution (Life 
Technologies catalog number #11430030), 1 ml of 85% (weight/volume) sodium chloride in 
1M HEPES, 1.5 ml. of 100X antibacterial-antimycotic solution (Thermo Fisher Scientific 
catalog number #15240062) and 9.5 ml. of molecular grade water.  The vortexed cercarial 
solution was pipetted on top of the percoll gradient solution. Centrifugation was carried out 
at 900g for 45 minutes at 4°C. 
Post centrifugation, the tails accumulated at the top of the percoll were discarded, and 
the somules collected as a prominent pellet at the bottom of the tube. The somules were 
washed once with sterile Dulbecco’s phosphate buffered solution (DPBS) (Thermo Fisher 
Scientific catalog number #14190250) and centrifuged at 20 minutes at 500g at 4°C. The 
recovered pellet containing the purified somules was dissolved in 500 µls. of sterile DPBS. 
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2.3.4. Selection Of Neuropeptides 
11 peptides were chosen and synthesized by the company Peptide 2.0 (Chantilly, VA 
20153-3983, USA) : SAYPYV-NH2 (Reference number #50647-649), SYFDPIIY 
(Reference number #50647-923), VPPYITGGIRY (Reference number # 50647-925), 
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AYHFFRL (Reference number # 50647-926), FLFNLKDTRW-NH2 (Reference number # 
50647-653), GFVRI-NH2 (Reference number # 50647-642), AFVRL-NH2 (Reference 
number #50647-641), GMI-NH2 (Reference number # 50647-643), YIRF-NH2 (Reference 
number #50647-934), NYLWDTRL-NH2 (Reference number # 50647-650) and DDFRG-
NH2 (Reference number # 50647-651) [80, 121]. All the peptides were delivered as 
lyophilized material and dissolved at a concentration of 1 mM in double distilled, molecular 
grade water. The diluted peptides were stored at -20°C.  
2.3.5. Testing Neuropeptides on Somules In A 6 Welled Plate 
Freshly isolated S. mansoni somules were added to 6 welled cell culture, non-
pyrogenic, polystyrene plates (Corning Incorporated catalog number #3506) containing 
Basch Media (the protocol was provided by the Caffrey lab at the Skaggs School of 
Pharmacy and Pharmaceutical Science, University of California San Diego, USA as well as 
published) [122] . To the somules, a 1:1 dilution of neuropeptides (diluted in Basch media) of 
varying concentrations per well i.e. 0.1 µM, 1.0 µM, 5 µM, 10 µM, 50 µM and 100 µM, 
were added and were incubated for 30 minutes at 37°C. Motility of the somules were 
recorded for 5 minutes, at the rate of 10 somules per view through a 10X objective lens of a 
compound microscope (Nikon Eclipse TS100), equipped with a digital camera ( Zoom Nikkor 
ED Glass 5.0 Mega pixels 8X zoom, electric view finder).  The resulting videos were then 
imported and analyzed by the wrMTrck plugin of Image J. Serotonin hydrochloride (Sigma 
Aldrich catalog number # H9523) was used as a positive myo-excitatory control as it can 
stimulate movement [77]  and carbamoyl choline chloride (Sigma Aldrich catalog number # 
C4382) was used as negative control, as it can inhibit movement [77] . Both products were 
used at the following concentrations: - 0.1µM, 1µM, 5µM, 10µM and 100µM.  Animals are 
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classified as “motile” if they actively moved on the plates without stimulus, they are 
classified as “limited mobility” if they move with relatively slow movement or they are 
denoted “non-motile”, if the worms were immobile and did not respond to any external or 
internal stimuli [93, 120]. Unhealthy worms were ignored during recording.  
2.3.6. Manufacture of The Microfluidic Platforms 
S. mansoni somules were not capable of moving laterally in each well of the 6-welled 
plate, so microfluidic platforms with sinusoidal channels were designed. The protocol for the 
manufacture of the microfluidic platforms was followed as published before [101, 123, 124]. 
The microfluidic chips were fabricated in the lab of Dr. Santosh Pandey’s micro/nano 
systems laboratory of the Electrical and Computer Engineering department of Iowa State 
University, using a standard soft photolithographic process [123-127]. Polydimethylsiloxane 
polymer or PDMS (Catalog number # Sylgard 184 Silicone Elastomer Kit, Dow Corning 
Corporation, Midland, MI), which is known to be biologically inert, transparent and glass 
permeable, was mixed and poured over the SU-8 photoresist mold (Catalog number # 
Microchem Corporation, Newton MA), which was then allowed to solidify. Once solidified, 
the PDMS was peeled off the SU-8 mold, followed by input and output holes being punched 
into the device. Air plasma was used to bond the PDMS device to individual glass slides 
following a published protocol [123-127]. 
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Table number 2.1. List of the neuropeptides, along with their associated npp genes, from 
which they originated. 
 
 
Since S. mansoni somules in a well plate is unable to move laterally in the well, 
sinusoidal channels (width of each channel = 60 microns, amplitude = 220, channel 
wavelength = 360) were designed on the microfluidic chip which could imitate human blood 
vessels which aid in somule propulsion. The fixed amplitude and the wavelength allowed the 
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researcher to control the parasitic waveform and trajectory with limited latitudinal and 
longitudinal freedom [123-127].Adequately designed sinusoidal parallel channels were 
designed so as to allow multiple subjects to be viewed at the same time during a single 
microscopic recording. The S. mansoni somules were added to the reservoirs using a 1 ml. 
syringe, connected to a polyethylene tubing.  
However, it was found that the somules would end up being flushed out of the 
channels whenever the chip was moved, or fluids were added to the ports.  Microscale filters 
were attached to the reservoirs on either side of the wave like channels to prevent the rapid 
movement of fluids in the channel which could flush the somules out of the chip. The 
movement of somules was recorded for 5 minutes, using a 10X objective lens of a compound 
microscope (Nikon Eclipse TS100), equipped with a digital camera (Zoom Nikkor ED Glass 
5.0 Mega pixels 8X zoom, electric view finder). The software used for recording the somule 
movement was Ken-a-Vision and the digitizer was connected to a USB 2760 camera. From 
previous research of studying the movement of C. elegans through similar microfluidic 
channels, the chips possessed certain advantages e.g. analyzing the unimpeded crawling 
motility of the schistosomules through the channels, the filters prevented the worms from 
being flushed out as well as high-thorough put pharmacological screening of the worms for 
potential anthelminthic agents as well as limiting the influence of the external environment 
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[125, 126].
 
2.3.7. Media Used For The Microfluidic Platforms 
Basch media was made in the following way: - 9.23 gms. of MEM with Earl’s Salt, 
without L-glutamate, phenol red, sodium bicarbonate (JRC catalog number # 56-119-000) 
was dissolved in 1 liter of distilled water, followed by 1000 mgms. of glucose (Fisher 
Scientific catalog number # D-16-3) and 2400 mgms. of HEPES (Fisher Scientific catalog 
number # 6003H). 1000 milligrams of lactalbumin hydrolysate (BRL Catalog number # 
11800-025) was added to the mixture and it was allowed to dissolve for 15-20 minutes on a 
magnetic shaker. Once dissolved, 2.2 gms of sodium bicarbonate (Corning Cellgro catalog 
number # 90-009-PB) was added to the media. 500 µls. of 1 mM hypoxanthine (Sigma 
catalog number # H-9377), 500 µls. of 1 mM hydrocortisone (Sigma catalog number # H-
0888), 500 µls. of 1 mM triiodothyronine (Sigma catalog number # T-5516) and 900 µls. of 
bovine pancreas insulin (Sigma catalog number # I-5500) was added to the mixture, after 
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which the pH was adjusted to 7.3-7.4. 50 µls. of 1X Schneider’s media (Invitrogen catalog 
number # 11720-034) and 5 ml of 100X MEM Vitamins (Invitrogen catalog number # 
11120-052) were added and the pH was again calibrated to 7.3-7.4. The entire media was 
filter sterilized and to the sterile Basch media, 500 uls. of penicillin-streptomycin and 50 µls. 
of 5% re filtered, heat inactivated fetal bovine serum (JRS catalog number # 43640-100) was 
added. Aliquots of 50 ml were made and stored at 4°C. 
One of the major problems of using a complete fluid media like Basch, was that 
somules were floating along with the flow of the media and not exhibiting any muscular 
function for locomotion, which is what we need to observe. In the human host, parasites 
cannot float that easily through blood vessels due to narrow size of the vessels and also 
because of the presence of red blood cells, white blood cells and platelets. To mimic this 
situation, different media were tested, to determine the ideal one in which the somules could 
move freely without any obstruction. We tested different concentrations of agar dissolved in 
water (Fisher BioReagents OptiGrow Pre-Weighed LB Agar, Miller (Powder) catalog 
number #BP1425-10P1 – 0.1% 0.2% 0.3% 0.4%. The agar was maintained in a molten state, 
on a heated shaker. Somules were added to the agar, once it reached an ideal temperature so 
that the parasites could survive and freely move in it, without getting affected by the heat. 
Based on our trial runs, we believe maintaining the agar media at a temperature range of 
50°C- 60°C was suitable for the somules to exist. When the temperature of the agar was 
higher than the observed range, it caused the heating up and destruction of the worms, and 
when the temperature of the agar was lower than the range, the media was solidified thus 
restricting the movement of the worms. In addition to agar, we also tested other media such 
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as collagen (Advanced Biomatrix PureCol EZ Gel catalog number # 5074-G), pluronic gel 
(Sigma Aldrich number # 435422-250ML). 
2.3.8. Analysis of The Videos 
The videos recorded from the 6 welled plates were imported into wrMTrck plugin of 
Image J software for analysis [77]. The recorded video images of worms are converted to 
binary objects through the software, which is then tracked from one frame to the next [77] . 
The phenotypic motility of the somules were measured in terms of body contractions, using 
the parameter Body Bends Per Second (BBPS). This parameter has been previously used to 
record the phenotypic motility of C. elegans [128]. Based on the definition of BBPS as 
provided by [128], the contraction of muscles which caused the C. elegans to bend on one side 
was considered as 1 body bend [128]. During analysis, when the somule made 3.5- 4.0 BBPS, 
this movement was considered as “normal swimming”. Movements recorded with fewer or 
more BBPS due to a different posture of the worm was considered “abnormal swimming” 
when compared to the control movement [128] . Based on the data obtained from the Image J 
wrM Trck software, graphs were created using Graph pad Prism version 8. Videos recorded 
from the microfluidic platforms were uploaded to the Iowa State University cloud Cybox 
storage, allowing collaborators access to the data. Dr. Zach Njus from Dr. Santosh Pandey’s 
lab wrote a custom computer program to interface with the scanner, in order to analyze the 
videos.  
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2.4. Results and Discussion 
2.4.1 Testing The Neuropeptides On S. mansoni Somules Motility In A 6 Welled Plate 
Based on initial experiments, 3 out of 11 neuropeptides were found to have a visible 
effect on the motility of the S. mansoni somules- GFVRI-NH2, AFVRL-NH2 and YIRF-
NH2 (data not shown). These three peptides were chosen for further experiments. 50 S. 
mansoni somules were added to each well of a 6 welled-plate in 3 ml. of sterile Basch media, 
each well containing a different concentration of each neuropeptide ranging from 0 µM, 1 
µM, 5 µM, 10 µM, 50 µM and 100 µM. For each peptide-treated plate, a positive control, 5-
HT and a negative control, carbachol were maintained. All plates were incubated for 30 
minutes at 37°C and the motility of the somules were recorded for 5 minutes, at the rate of 10 
somules per view, using a compound microscope (Nikon Eclipse TS100), equipped with a 
digital camera ( Zoom Nikkor ED Glass 5.0 Mega pixels 8X zoom, electric view finder).The 
resulting videos were imported into wrM Trck plug-in of Image J software for analysis. 
Somules moved forward using a specific head-to-tail propagation of dorsal and 
ventral body bends [126]. In order to quantify the motility of worms, the software calculated 
the average number of subtracted pixels/frames to the total number of pixels in the binary 
object  [77]. The phenotypic motility of the somules was measured in terms of body bends 
per second (BBPS).  
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In S.mansoni adult worms and cercariae, the neuropeptide precursor Sm-npp-1 
encodes  GFVRI-amide [80]. The neuropeptide GFVRI-amide is expressed in the cerebral 
ganglion neurons of the central nervous system (CNS) in  S.mansoni adult worms and 
schistosomules and is believed to be responsible for interneuronal communication [80]. The 
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application of GFVRI-amide to isolated muscle fibers from somules, caused a visible 
inhibitory effect on the somule motility, which was assumed to be a result of spastic 
(myoexcitatory) or flaccid (muscular relaxation) paralysis [80].  
In our experiments, when GFVRI-amide was applied to S. mansoni somules in a 
concentration dependent manner, there was an initial reduction in somule motility at 1µM 
concentration, followed by a significant increase in somule motility starting from 5µM 
concentration to 100µM concentration of GFVRI-amide. When compared to the untreated 
control, GFVRI-amide had a significant increase in somule motility. Unfortunately this result 
seems confusing and does not correspond with previous published data, which displayed an 
inhibition of S.mansoni adult and somule muscular movement [80]. 
In S.mansoni adult worms and cercariae,  Sm-npp-1 precursor also encodes the 
AFVRL-amide [80]. AFVRL-amide was also identified in Eisenia fetida, however not much 
information is available regarding the function of this peptide in helminths [116]. When we 
treated schistosome somules with AFVRL-amide, there was a slight reduction in somule 
motility at 10µM concentration, after which there was an increase in motility starting from 
50µM-100µM concentration of AFVRL-amide. When compared to the untreated control, 
AFVRL-amide seems to increase somule motility.  
YIRF-amide is a FMRF-amide like protein or (FLP), which was first isolated from a 
horseshoe crab commensal Bdelloura candida and the NP caused a dose-dependent 
contraction in turbellarian muscle fibers [129].  YIRF-amide is abundantly distributed 
through the central nervous system of platyhelminths as well as in the nerves innervating the 
reproductive and somatic muscular systems [106, 107, 112]. In 2007, the very first 
platyhelminth NP receptor, GtNPR-1was identified from G.tigrina and is believed to be the 
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main receptor responsible for neuromuscular excitation in platyhelminths [106, 112]. The 
mode of action of GtNPR-1 is via the GPCR signal transduction pathway, in which the 
receptor is coupled to the Gai/o subunit, and once the FLP binds to the receptor, the 
phospholipase C-b (PLC-b) mediated downward pathway is activated, leading to the 
activation of protein kinase C (PKC) [106, 107, 112, 130]. Upon activation, PKC translocates 
to the cellular plasma membrane, resulting in muscle contraction in platyhelminths [106, 
130]. In 1997, YIRF-amide was found to increase muscular contraction in somule and adult 
schistosomes, thus being myoexcitatory in nature [112, 115]. However, this result was 
contradicted in 2011, since YIRF-amide was found to inhibit schistosome worm movement 
[80].  
Our experiments demonstrate that when YIRF-amide was applied to S. mansoni 
somules in a concentration dependent manner, there was an initial reduction in somule 
motility starting from 5µM concentration, followed by an increase in somule motility starting 
from 10µM concentration of YIRF-amide. Overall, there seemed to be an inhibition in 
motility of the treated somules, when compared to the untreated controls. This seemingly 
corresponds with the results published in 2011 by McVeigh’s group, which displayed an 
inhibition of somule muscular movement [80] 
In this assay, the motility of the parasites was analyzed and expressed using the 
parameter body bends per second (BBPS). However, this parameter is not sufficient to 
understand and analyze the effect of drugs on the directional motility of the worms. In order 
to ensure the effectiveness of a newly synthesized anti-schistosomal drug, it is necessary to 
study if the drug has any effect on the forward movement of the somule, and not just on its 
motion at a singular point. This is an important deficiency of this assay, since the 6-welled 
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plates are unable to mimic the host environment in which somules can survive and travel 
through the body.  
2.4.2 Analysis of The Movement of Schistosoma mansoni Somules Through the 
Microfluidic Channels Using A Custom Computer Program Designed by Dr. Zach Njus 
In recent years, microfluidic technology has gained a lot of attention as a more ideal 
form of motility assays. The effect of chemotherapeutic agents on organisms within custom-
designed chips can help researchers  study and analyze the resultant chemotactic behavior of 
the animals [92]. For our experiments, it was necessary to study the migration of S. mansoni 
somules through narrow channels that could mimic the mammalian circulatory system and 
these platforms were manufactured by Dr. Zach Njus and Dr. Santosh Pandey’s micro/nano 
systems laboratory of the Electrical and Computer Engineering department of Iowa State 
University. We hypothesized that these microfluidic channels could help researchers develop 
better and more reliable drug screening assays while assessing worm viability.  
The microfluidic channels are organized as sinusoidal channels and the width of each 
channel is 60 microns with an amplitude of 220 and a channel wavelength of 360. After 
transforming freshly shed S. mansoni cercariae into somules, the somules were added to the 
opening pores of the microfluidic channels using a 1 ml. syringe connected to a polyethylene 
tubing. The movement and migration of the worms through the channels were recorded for a 
period of 5 minutes. Since the somules are in a constant state of occlusion with the side walls 
of the sinusoidal channel of the microfluidic chip, Dr. Pandey’s group designed a custom-
made software program which characterized the structure of the somules based on 3 
parameters, texture, shape and size. Initially, the bright field video of the somule moving 
through the microfluidic channel was observed, which was then segmented based on 
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intensity and texture from the video, and finally a visual representation of the data in video 
format was used for verification and analysis. This program tells the scanner when to take a 
picture, how often to take pictures, how many pictures to take and then analyze the pictures 
when done. A climate control system was created because these experiments took so long, 
the climate in the lab could be subject to fluctuating temperatures. The protocol of software 
analysis was divided into a number of steps. As per previous publications, a body movement 
is defined by a displacement of pixels in between two consecutive frames [77]. The unit 
“pixel” is used to measure the width or height of a worm image, and hence in this study, the 
term has been utilized to measure length and distance [131].  
The first step of the software analysis involved channel segmentation, a background 
image was made by looping through the video frames and recording the brightest pixel value 
taken during the video, thus effectively erasing the worm from the frame.  This allowed the 
channel of the microfluidic device to be segmented based off of color and size. The second 
step of the software analysis involved segmenting somules from the video. A standard 
deviation filter was taken across the original image to highlight areas with a high texture 
value.  
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The two key parameters used for expressing the movement of somules within the 
microfluidic channels were (1) Centroid Distance and (2) Track Distance.  These terms were 
introduced by Dr Zach Njus.  
(1) Centroid Distance is defined as the point whose coordinates demonstrate the mean 
value of the coordinates of all the points (expressed in pixels) which in turn, represents the 
subject under study i.e. somule in this case (as opposed to ‘background’) in a binary worm 
image [131]. The centroid distance represents the body movement of the somule, as it 
expands and contracts at one point .Once the schistosomules were placed into the 
microfluidic channels by a wide-bore pipette, the movement of the worms was tracked over a 
specific time period (typically 10-15 minutes); this provided the velocity of the body centroid 
[103].  
(2) Track distance represents the distance moved by a somule from one point to the 
second point. The ratio of the distance traversed by the worms through the sinusoidal 
channels from one point to the second point, to the net change in time, was calculated to 
provide the track distance [120]. 
For our experiments, the movement of somules through the channels was recorded for 
5 minutes, using a 10X objective lens of a compound microscope (Nikon Eclipse TS100), 
equipped with a digital camera (Zoom Nikkor ED Glass 5.0 Mega pixels 8X zoom, electric 
view finder). 
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The videos were analyzed using the software custom made by Dr. Njus and Dr. 
Pandey. The centroid distance (expressed in pixels) and the track distance (expressed in 
pixels) of the S. mansoni somules treated with 100µM of each neuropeptide were compared 
against the untreated control, a positive control of 100µM 5-HT and a negative control 
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of100µM carbachol .5-HT was chosen as the positive control in this assay because it causes 
hypermotility in S. mansoni via rapid contraction of the longitudinal muscles and cross-
sectional constriction of circular muscle, leading to rapid elongation, by modulating neuronal 
output to the parasitic muscles [77] . Carbachol is a cholinomimetic agent and an inhibitor of 
acetylcholinesterase which binds directly to mammalian post synaptic nicotinic cholinergic 
receptors and can produce flaccid paralysis in schistosomes, making carbachol an ideal 
negative control [132]. Based on the results we obtained, S. mansoni somules treated with a 
high concentration of AFVRL-amide, showed the maximum movement at a single point 
when compared to the untreated control, however the distance moved by these treated 
somules was less, when compared to the untreated control. Since the effect of the 
neuropeptide AFVRL-amide on helminths has not been much explored, we can assume that 
the peptide has a myoexcitatory effect on the somules.  
A literature review conducted on previously published research on the effect of 
YIRF-amides on S. mansoni somules, gave us contradictory results. In 1997, it was 
demonstrated that YIRF-amide had a myoexcitatory effect on somules, causing rapid 
muscular excitation and contraction in the parasite [115]. But in 2011, the same peptide was 
found to inflict inhibitory effect on the muscular movement of the somules [80]. Our results 
correspond with the data published in 1997 by the Day group, since there seemed to be a 
visible increase in centroid distance when the somules were exposed to YIRF-amide, when 
compared to the untreated control. Hopefully this data will help to support the hypothesis that 
YIRF-amide is myoexcitatory for parasites.  
Previously it was established that the neuropeptide GFVRI-amide has an inhibitory 
effect on the muscular activity of S. mansoni adult worms and somules [80]. The data we 
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present here, corresponds with the previously published data. When the somules were treated 
with GFVRI-amide, there was a reduction in the motility of the worms, when compared to 
the untreated controls.  
From the data we obtained above, we can hypothesize that motility of a parasite at a 
singular point in not indicative of its directional movement. Just because the parasite displays 
rapid myoexcitatory activity, does not essentially mean that the parasite is capable of moving 
ahead. We demonstrated that AFVRL-amide treated S. mansoni somules displayed a high 
contractile activity, however it is unable to move ahead, when compared to the untreated 
controls. Similarly, the parasites treated with YIRF-amide showed high muscular contraction, 
but again the distance travelled is insignificant, when compared to the untreated controls. The 
pattern was repeated in the somules treated with GFVRI-amide. It can be assumed that the 
somule uses up all its energy during rapid muscular expansion and contraction, and it is 
possible that this high activity exhausts the parasite, as a result of which it is unable to move 
ahead. We can thus hypothesize that contractile activity is not directly proportional to 
directional motility. To prove the hypothesize, we conducted the next set of experiments, the 
results of which confirmed our proposed theory.  
2.4.3 Analyzing the Relationship Between Contractile Activity and Directional Motility 
of S. mansoni Somules  
Contractile activity is defined as the contraction of the cell, depending on the activity 
of the major axis along the length of the cell and minor axis along the width of the cell [44]. 
Directional cell motility is initiated as a result of a functional asymmetry between the front 
and the rear of the cell, due to the presence of a steering mechanism, which produces 
persistent self-propagated polarization [121]. In order to differentiate between the two 
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parameters, S. mansoni somules were treated with different concentrations of 5-HT (1µM, 
5µM, 10µM, 50µM and 100µM). As mentioned before, the motility and migration of the 
somules through the channels were recorded for 5 minutes, using the same equipment as used 
before, and the videos were analyzed using the Njus-Pandey software. 
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From figure number 2.4.O, it is obvious that the activity of the somule increases 
proportionally when exposed to increasing concentration of 5-HT, however the distance 
moved by the somules decrease at the same concentrations of 5-HT. Figure 2.4.P suggests 
that the contractile motility of the parasite is inversely proportional to the directional motility. 
This supports our proposed hypothesis that when the activity of the somule increases, it uses 
up its energy, which leaves it exhausted and unable to follow directions to move ahead 
through the host circulatory system. We can assume that while 5-HT is essential for the 
overall survival of the schistosome, too much of it can actually lead to its death. Although 
this looks like a possible route for designing chemotherapeutic drugs to prevent 
schistosomiasis, the consequence of having excessive serotonin in the mammalian body, is 
dangerous. At high doses of serotonin (70-200 mg/kg), a person can experience symptoms 
ranging from tremor, nausea, dizziness, delirium to severe side effects like muscle rigidity, 
seizures and in extreme cases, it could lead to death [133]. 
2.4.4 Choosing the Ideal Media for Microfluidic Assays 
To design a suitable and efficient microfluidic assay, it is important to choose an ideal 
media which can mimic the environment in mammalian blood vessels [101]. Human blood is 
made up of fluid (plasma) and cells (erythrocytes, leukocytes and platelets), so after 
schistosomules invade humans, they have to navigate through a complex network to spread 
the disease.  Controlling  of the flow of the media or fluid is important in biological assays 
[92]. One drawback of using liquid media like Basch media in microfluidic assays, is the 
tendency for the media to produce an internal fluid pressure in the channels that could 
directly affect the somules’ natural movement; as a result, the somules may float in the 
medium, rather than move normally, which can be observed under a light microscope [134] . 
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An additional problem with Basch media is that it tends to contaminate quickly as a result of 
its rich composition. To improve our microfluidic setup, it was necessary to imitate the 
conditions undertaken by the somules as they travel through the human system to their final 
destination. In a previous publication, the Pandey group studied the movement of C. elegans 
in 0.7% agarose dissolved in M9 buffer within the microfluidic channels, their reasoning 
being agarose provided a suitable resistance for the worms unlike fluid media [134]. In our 
study, 0.7% agarose dissolved in distilled water was found to be too dense for the worms to 
move freely (data not shown). We therefore tested the motility of somules in lower 
concentrations of agarose dissolved in distilled water, collagen and pluronic gel, using fluid 
Basch media as the control for comparison. The motility of the somules traveling through the 
microfluidic platforms was recorded as per our previous protocol and the videos were 
analyzed using the Pandey-Zach software program. 
In Basch media the schistosomules tend to float, rather than move on their own 
through the channels. The drawback of using different concentrations of agarose is 
maintaining each at reasonable temperatures, to prevent the agar from solidifying. 
The third media which was tested was biocompatible pluronic F-127 gel solution which had 
been previously used to study the movement of C.elegans through microfluidic channels 
[135]. Unfortunately, pluronic gel was not very helpful because of its constant fluctuation 
between fluid media and gel media at the slightest change in temperature.  
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Maximum contractile activity of the somules was observed in pluronic gel and 
minimum contractile activity was seen in 0.1% and 0.3% agarose media. The distance 
travelled by the somules was highest in collagen and the minimum distance was covered by 
the somules in 0.1%-0.3% concentration of agarose. But it was observed that when somules 
were in pluronic gel, the track distance covered by the somules was very low. This indicates 
that the somules had restricted movement in pluronic gel. However, the centroid distance 
covered by the somules in collagen and the track distance travelled by the somules were high. 
This would indicate that although collagen provided some amount of restriction to the 
somule mobility, it also allowed the somule to move ahead easily. One drawback of using 
collagen was its tendency of solidifying at a slight increase in temperature.  Fortunately, this 
solidified media could be reversed immediately to fluid media by placing the collagen on ice. 
Therefore, we can conclude that collagen is a good media to test the movement and activity 
of worms in microfluidic assays. 
2.5. Conclusion 
 
Schistosomiasis is a freshwater borne parasitic neglected tropical disease (NTD) 
caused by parasitic worms belonging to the genus Schistosoma. According to reports filed by 
World Health Organization (WHO), NTDs have been reported in at least 149 countries, 
where it affects more than one billion people worldwide. Intestinal schistosomiasis is caused 
by Schistosoma mansoni, which is widely prevalent in Africa, the Middle East, parts of South 
America as well as Asia. The recommended drug to combat this parasitic disease is the 
affordable and relatively safe anti-parasitic drug praziquantel (PZQ) [67]. 
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Table number 2.2. Table representing the advantages and disadvantages of different media to 
use in microfluidic devices. 
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PZQ acts by increasing the permeability of the parasitic membrane, thus allowing a 
rapid reflux of calcium ions through voltage operated calcium channels (VOCC) [54]. 
Recently there have been reports of drug resistant S. mansoni worms, from various African 
countries like Egypt and Kenya [8, 11]. Another major disadvantage of PZQ is that the drug 
can act against adult worms but is not very effective against juvenile worms. There is an 
urgent need for new, specific and highly effective anti-schistosomal drugs, and also the 
pressure to develop  efficient platforms for easy detection of the disease [70]. Early detection 
of schistosomiasis can help researchers to design better assays in order to test the effect of 
novel drugs on parasites.  
Both nematodes and flatworms express a large number of helminth neuropeptides 
however, the functions of all the peptides is not completely known .Many  of these 
neuropeptides have been shown to be widely distributed throughout the nervous system of 
flatworms and are involved in the contractile and regulatory activities of the organisms [79, 
80, 114]. These worm-specific neuropeptides and their as yet unidentified receptors have the 
potential of being possible anthelminthic drug targets, capable of overcoming the emergence 
of PZQ drug resistance and introducing better anthelmintic therapeutic agents. 
One of the major challenges when it comes to  monitoring and treating of parasitic 
diseases, is the lack of a sensitive, simple and cheap biological assay [136]. In recent times, 
microfluidic devices or “Lab-on-a-chip” technology, which are miniaturized versions of 
macroscale systems, have become popular in biological applications such as 
electrophysiology, pharmaceutical analysis, screening of drugs, analysis of cells and cellular 
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materials, separation and screening of biomolecules, diagnostics, and tissue engineering [92]. 
Microfluidics have been used previously to study the movement of C. elegans [93, 120]. This 
assay has many significant advantages such as the integration of an entire lab on a single 
small chip; working with reduced chemical and fluid volumes, thus eliminating wastage and 
lowering costs,  reduced reaction times, faster screening of novel compounds, simpler, 
quicker, portable, affordable manufacture as well as the ability to study several experiments 
simultaneously  [96, 119, 137]. In addition, the process of fabrication of the microfluidic 
chips is standardized with  consistent reproducibility with increased sensitivity and increased 
resolution, allowing easy handling, which would otherwise be a time consuming and 
laborious process [33, 119, 137] . Hence its popularity has sky rocketed in the world of 
modern biology and biotechnology.   
In this paper, we have presented and demonstrated specially manufactured 
microfluidic chips to study the movement and behavior of S. mansoni larval parasites as they 
move through the sinusoidal channels designed on the chips, thus mimicking the host 
environmental conditions. The microfluidic platforms were made of gas permeable and 
visible PDMS irreversibly bound to glass slides using soft lithography. Each chip had a 
number of sinusoidal channels running parallel to each other, so that multiple experiments 
could be carried out simultaneously. To analyze somule motility, the Njus-Pandey research 
group created a custom software program using two parameters (1) centroid distance to 
measure the activity of the somule at one point, and (2) track distance to measure the distance 
covered by the worm from one position to the other. Of the 11 chosen neuropeptides, 3 
peptides were selected for further studies to test the effect of each NP on somule motility. 
The 3 peptides were AFVRL-amide, GFVRI-amide and YIRF-amide.  
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When the first set of experiments were conducted in 6 welled plates, it was observed 
that the motility of the somules increased with an increase in concentration of GFVRI-amide 
as well as AFVRL-amide and there was a substantial decrease in somule motility with an 
increase in the concentration of YIRF-amide. The results we obtained from the GFVRI-
amide treated somules did not correspond with previously published data, which had stated 
that GFVRI-amide has an inhibitory effect on S. mansoni adults and somules [80]. In 
addition, the data we obtained from the YIRF-treated somules did not match with those 
published in 2011, which stated that the peptide had an inhibitory effect on the worms [80]. 
However our results did agree with those published earlier in 1997 by Day et al, which  
suggested that YIRF-amide had a myoexcitatory effect in somules [115].  
In our second state of experiments, we introduced the drug treated somules to 
microfluidic channels, and the movement was recorded for 5 minutes. Using Dr. Njus’ 
custom software program, the video recordings were analyzed, and it was confirmed that the 
schistosomules treated with 100µM of AFVRL-amide displayed maximum centroid distance 
and those treated with 100µM of GFVRI- amide displayed minimum centroid distance, when 
compared to the controls. In other words, AFVRL-amide caused the worms to undergo high 
levels of contraction and expansion at one point, whereas GFVRI- amide caused the somules 
to demonstrate minimum expansion and contraction. This result corresponds with the data 
published by McVeigh et al. in 2011 [80]   
On the other hand, somules treated with 100µM of YIRF-amide demonstrated the 
maximum track distance i.e. these schistosomules covered the maximum distance from one 
point to the second point. The somules treated with 100µM of GFVRI-amide demonstrated 
the least track distance i.e. the schistosomules covered minimum distance between two 
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points. These results introduced another novel hypothesis i.e. contractile activity of worms 
was inversely proportional to directional motility of the worms. In other words, the more a 
parasite exhibits activity at one point, less is the distance it can travel. To prove this 
hypothesis, we tested somules with increasing concentrations of 5-HT and it was observed 
that centroid distance of the somules increased whereas the track distance decreased. This 
conclusively proves that contractile activity was inversely proportional to directional 
motility. 5-HT is widely distributed throughout the central and peripheral nervous system, 
and plays an important role in worm motility, glucose uptake, carbohydrate metabolism to 
produce energy and directly affect the body wall muscles of the worm [77]. It was proposed 
that the hyperactivity of the 5HT treated somules caused a depletion in the energy stores, and 
this lack of energy prevented the somule from performing other activities, like migration. So, 
although the viability of the somule is dependent upon 5-HT, exposure to higher 
concentrations of 5-HT would destroy the somule.  
In order to improve the microfluidic chip, it was of great importance to choose a 
suitable media, through which the schistosomules could move ahead easily, with minimum 
resistance. Of all the different types of media tested, we believe that collagen was the ideal 
media to use in microfluidic assays.  
Although this microfluidic assay seems promising for future research, it is not a 
perfect device, and requires improvement. The addition of a chemoattractant at the end of the 
channel might be a good idea to test for future experiments, so that the parasites have 
incentive to move forward and not get stuck at one place. Here, we present a novel assay to 
analysis and quantify the movement of S. mansoni somules through microfluidic chips. We 
hope that our method will potentially help researchers to study the parasitic motility and its 
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role in the spread of the disease, assisting scientists in developing better and effective drugs 
therapy. 
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CHAPTER 3. A QUANTITATIVE AND QUALITATIVE PROTEOMIC ANALYSIS 
OF SCHISTOSOMA MANSONI CERCARIAL TAIL PROTEINS 
 
Modified from a paper to be submitted to PLoS Pathogens 
Sreemoyee Acharya1,3,4, Gunnar R. Mair1, Tim A. Day1,4 
3.1 Abstract 
 
Schistosomiasis is caused by the blood fluke Schistosoma mansoni and is responsible 
for infecting 200 million patients worldwide; it is a key neglected tropical parasitic disease 
(NTD) [4, 12, 71, 95, 96] . An infection is initiated when the larvae, known as the cercariae, 
are released from its intermediary host, a Biomphalaria freshwater snail, into the surrounding 
water. Cercariae are free swimming, highly motile forms with specialized bifurcated tails that 
approach the host tail-first and penetrate the mammalian skin thus infecting the human host 
[27, 95, 138]. Following attachment and during invasion, the cercaria sheds its tail and the 
resulting somule continues to develop inside the circulatory system of the host body [32]. 
Cercarial tail motility plays an essential role in host localization and survival of the parasite 
outside the mammalian body, yet the proteins supporting this prolonged and vigorous 
movement are poorly understood. In this study, we have extracted and identified the 
proteome of isolated cercarial tails and bodies using mechanical transformation of cercariae 
into somules. Using mass spectrometric analyses, we identified a total of 945 proteins in the 
combined cercarial proteome from four independent samples: 791 proteins accumulated in 
the cercarial tails and 645 proteins were identified from the somule bodies. By determining 
the function and localization of specific proteins in the cercarial body, we hope to propose 
possible therapeutic mechanisms via which host skin invasion by these parasites can be 
avoided. 
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3.2 General Introduction 
3.2.1. Life Cycle of Schistosomes 
Schistosomiasis is a major neglected tropical diseases (NTDs), only second to malaria 
in the list of devastating parasitic diseases. According to the World Health Organization 
(WHO) and the Centers of Disease Control (CDC), more than one billion people are affected 
by NTDs in at least 149 countries [1-4]. The disease can be either acute or chronic [4] .The 
three species belonging to the genus Schistosoma capable of infecting humans are 
Schistosoma mansoni and Schistosoma japonicum that can cause intestinal schistosomiasis 
and Schistosoma. haematobium that causes urogenital schistosomiasis [4, 12, 96]. As per 
reports filed by WHO schistosomiasis is very prevalent in tropical and subtropical countries, 
in poor communities with no access to safe drinking water, limited scope for education, food 
insecurity and poor sanitation [3, 6, 139] . People who are involved in routine agricultural or 
domestic occupations and school-aged children are especially prone to infection, since they 
are constantly in contact with contaminated water. 
The eggs of the parasites hatch in freshwater, releasing free-living, non-feeding 
miracidia which then proceed to infect an intermediate snail host [4, 22] . Each species 
completes the asexual phase of the life cycle in the first host e.g. S. mansoni and S. 
haematobium develop inside the aquatic freshwater Bioamphalaria and Bulinus snails, 
whereas S. japonicum needs a freshwater Oncomelania species of snails [4]. The cercariae 
matures and develops into multicellular sporocysts, which then transform to produce 
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thousands of free swimming cercariae [6]. The approximate length of a cercaria is between 
300-500 µm and the width are about 70 µm [27, 28]. Upon release from the snail, the highly 
infectious cercariae seeks to penetrate a mammalian host within a time span of 2 days or 48 
hours because they rely on the glycogen stored in their bodies to for swimming [3, 4, 23, 30-
32]. During the process, they shed their bifurcated tails and develop into schistosomules [4, 
8, 13, 22].  The somules course through the host circulatory system to the liver, where they 
settle within the superior mesenteric venules, and transform into adult male and female 
worms [4, 8, 13, 22]. The adult male and female mate and the female worm produces around 
100-300 eggs per day [4]. Some of the eggs are secreted via urine or stool into freshwater, 
whereas others accumulate in the host tissues and organs where they can lead to 
inflammation, resulting in the spread of the disease [4].  
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3.2.2. The Application of Proteomics in Parasitology 
Proteomics is the large-scale experimental analysis of proteins of a cell line, tissue or 
organism, and it allows an in-depth study of cellular systems e.g. the phenotype of cells, 
biological mechanisms, protein modifications, protein localization and compartmentalization, 
protein-protein interactions and the novel drug targets [94]. With improvements in mass 
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spectrometry, the development of databases and the creation of new computer algorithms, 
there have been significant advances in proteomic interpretation and protein expression 
profiling [94]. The genomes of S. japonicum and S. mansoni as well as the genome of the 
Bioamphalaria glabrata  have been sequences and analyzed, thus assisting in better 
understanding of parasite biology [22, 66, 95, 140]. A large transcriptome database 
containing resources for peptide sequences for S. mansoni was published in 2003 [141]. The 
proteomic analysis of different subset protein groups belonging to the interaction between the 
snail and the parasite has also been established, providing exclusive protein information of 
immature eggs [142, 143], secretions from the egg [144, 145] as well as its contents [142, 
146], the proteins involved in the excretory and secretory activities of the miracidia [147] and 
the proteins from the sporocysts [148, 149]. From the egg secretome, chaperone proteins 
such as heat shock proteins (HSP) as well as proteins involved in redox balance, protein 
folding [145]  were identified [146] and from the hatch fluid defense proteins were isolated 
[142]. Cytoskeletal proteins and proteases were observed from the immature eggs and the 
mature egg contents [142, 144]. From the miracidium to sporocyst stage, 127 proteins were 
identified such as those involved in larval transformation, protease inhibitors, chaperone 
proteins, antioxidant enzymes, ion binding proteins and venom allergen like proteins [142]. 
Novel biomarkers such as transferrin, a-1-antitrypsin and glutathione-S-transferase were 
identified in the serum of mice infected with Schistosoma mansoni parasites [150].  
3.2.3. The Significance of S. mansoni Cercarial Motility in Spreading Schistosomiasis 
The S.mansoni cercariae is highly mobile and infectious in fresh water for 
approximately 2 days or 48 hours [151]. Fluorescein isothiocyanate (FITC) labeled 
phalloidin staining of whole cercariae combined with confocal scanning laser microscopy 
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revealed the presence of diagonal muscles, longitudinal muscles and circular muscles in the 
cercarial body; striated muscles in the tail and longitudinal as well as circular muscles in the 
furcae [27] .  
 
Cercarial motility drives the rate of cercarial infectivity towards human skin thus 
dividing the movement into two phases (1) an active phase where the cercariae swim 
upwards and (2) a passive phase where the cercariae uses its forked tail as a drag anchor to 
sink down to the bottom of the fresh water body [152-154] . The swimming motion of the 
cercariae was first analyzed in 1967 by high speed photography [155]. Very recently, using a 
novel theoretical model and robotic structure designed by Dr. Manu Prakash’s group at 
Stanford University, the swimming behavior of cercariae was divided into three modes (1) a 
tail-first mode where the cercarial tail fork is fully extended and the cercariae moves against 
gravity (2) a free-sinking method where the cercarial tail fork is partially extended, making 
the parasite negatively buoyant and  (3) a head-first method where the cercarial tail fork is 
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folded back meant for  host penetration [152]. The cercarial tails are found to contain more 
glycogen as compared to the cercarial bodies, and the rate of glycogen use is significantly 
higher in the tail than in the body, which explains the aggressive motility of the tails [151]. In 
addition, the very active motility of cercariae depends on a number of environmental factors 
such as gravity, light, temperature and water turbulence as well as chemical gradients of skin 
and blood compounds of the human host [154, 156, 157]. These factors compel the cercariae 
to accumulate in the upper water layer which where they can come in contact with human 
hosts [152, 158, 159] . Once the cercariae penetrates into the human skin, the secretion of the 
acetabular glands occur in response to the host cues and chemical host signals, thus allowing 
the parasite to penetrate into the [158, 159].  
With the rise in the parasite resistance against commonly used drugs, there is an 
urgent need to identify novel chemotherapeutic targets. Since the cercarial tail is essential in 
identifying and penetrating the human host, we decided to concentrate on the cercarial 
proteins. Here, we present a completed proteomic analysis of the S. mansoni cercariae along 
with a comparison of the proteomic data between the parasitic bodies and the tails. We have 
also identified several proteins significantly abundant in the S. mansoni cercarial tail which 
have never been explored before and might possibly be potential drug targets. 
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3.3. Material and Methods 
3.3.1. Experimental Animals  
S. mansoni infected B. glabrata snails were provided by the NIAID Schistosomiasis 
Resource Center of the Biomedical Research Institute (Rockville, MD) through NIH-NIAID 
Contract HHSN272201000005I for distribution through BEI Resources. The snails were 
maintained at 26°C-28°C in charcoal-filtered, aerated water and fed fresh lettuce on a regular 
basis.  
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3.3.2. Cercarial Shedding Of Snails 
Approximately 30-40 S. mansoni infected B. glabrata snails were placed in a 250 ml 
glass beaker containing 40-50 ml of charcoal-filtered, aerated water (enough to cover the 
snails). Cercarial shedding was induced by exposing the snails to strong light for up to 2 
hours. The water from each beaker was filtered through a glass funnel (VWR catalog number 
# 89428-960) containing a 47-µM pore metal screen (VWR catalog number # 89428-966). 
The collected cercariae were transferred into a 50 ml. falcon tube and kept on ice causing the 
cercariae to settle at the bottom of the tube. Most of the supernatant was discarded, leaving 5-
10 ml. at the bottom of the tube.  
3.3.3. Transformation Of Cercariae To Schistosomules 
 In order to remove the tails from the cercarial bodies, the 5-10 ml. of cercarial 
solution was vortexed vigorously for 1 minute and then kept on ice for 1 minute. This cycle 
was repeated for 6-7 times. To check whether the tails had separated successfully from the 
cercarial bodies, 50 µl. of the sample was observed under a light microscope. 
Tails were separated from bodies by Percoll density gradient centrifugation.  40 ml. of a 60% 
Percoll solution were prepared from 24. ml Percoll (Fisher Scientific catalog number 
#45001754), 4 ml. of 10X MEM Vitamin solution (Life Technologies catalog number 
#11430030), 1 ml. of 85% sodium chloride in 1M HEPES, 1.5 ml. of 100X antibacterial-
antimycotic solution (Thermo Fisher Scientific catalog no #15240062) and 9.5 ml. of 
molecular grade water.  The vortexed cercarial solution containing separated bodies and tails 
was layered on top of the Percoll solution, taking care that the solution was not disturbed in 
any way. It was then centrifuged at 900g for 45 minutes at 4°C separating the tails from the 
cercarial bodies. 
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3.3.4. Collection Of Cercarial Tails And Cercarial Bodies  
Post centrifugation, the tails were collected from the top of the percoll solution, 
whereas the cercarial bodies (somules) were observed as a thick pellet at the bottom of a 
tube. Using a disposable Pasteur pipet (VWR catalog #14672-380), the tails were transferred 
 
109 
carefully from the top of the solution into a new 50 ml. falcon tube. The tails and the 
cercarial bodies were washed with sterile Dulbecco’s phosphate buffered solution (DPBS) 
(Thermo Fisher Scientific catalog #14190250) and centrifuged at 500g. for 20 minutes at 
4°C. The pellets from each sample—tails and cercarial bodies—were dissolved in 0.5 ml of 
DPBS.  
3.3.5. Protein Extraction  
Three independent cercarial sheddings were conducted on alternate days and the three 
tail samples were pooled into one tube. Similarly, three cercarial body samples were pooled 
into another tube. The tails and bodies (approximately 15,000-20,000 as counted using a light 
microscope) were lysed using a Fisher Scientific 60 Sonic Dismembrator with an output 
power at 100-Watt, frequency set at 22.5 KHz (Fisher Scientific 60 Sonic Dismembrator 
catalog # F60]. Each cycle was lysed for 1 minute, then kept on ice for 1 minute. In total 
there 4-5 cycles of lysing were conducted overall. The samples were centrifuged at 13,200 
RPM for 30 minutes at 4°C and the supernatant was collected as the crude extract. The pellet 
containing the remnants and debris was discarded. The concentration of protein in each tube 
was analyzed using the Bradford test, and the samples were submitted for mass spectrometry. 
3 repeats were performed for each individual body part of the cercariae (body n=3, tail n=3). 
3.3.6. Mass-spectrometric Proteomic Data Of Cercarial Tails And Cercarial Bodies.      
Crude protein extracts were digested in solution with trypsin/Lys-C. After digestion, PRTC 
standard (Pierce part #88320) was spiked into the sample to serve as an internal control. The 
peptides were then separated by liquid chromatography (HPLC: Thermo Scientific EASY 
nLC-1200 coupled to a Thermo Scientific Nano spray FlexIon source; Column:  Pulled glass 
emitter 75um X 20 cm (Agilent capillary, part #160-2644-5), packed with Agilent SB-C18 
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Zorbax 5um packing material (part #820966-922). Buffer A is composed of 0.1% formic 
acid/water and buffer B is composed of 0.1% formic acid/acetonitrile. The samples were 
analyzed by MS/MS (Thermo Scientific Q Exactive Hybrid Quadrupole-Obrbitrap Mass 
Spectrometer with an HCD fragmentation cell) by fragmenting each peptide. The resulting 
intact and fragmentation pattern was compared to a theoretical fragmentation pattern (from 
either MASCOT or Sequest HT) (Proteome Discoverer 2.1; Mascot against database of 
interest; Sequest HT against the PRTC database.) to find peptides that could be used to 
identify the proteins. The peak-area based quantification used precursor ions to assess the 
relative abundance of the identified peptides. The relative abundance of the identified 
proteins was based on the areas of the top three unique peptides for the identified 
protein. The PRTC areas were used to normalize the data between samples.  Each sample had 
the same amount of PRTC spiked in.   
3.3.7. Analysis of The Proteomic Data 
The analysis of the proteomic data obtained from the mass spectrometry facility was 
conducted in the following way. We identified each peptide hit using a genome database for 
eukaryotic and prokaryotic pathogens www.genedb.org. This data base provides information 
on the type of RNA of the peptide hit, the potential position, the length, the polypeptide 
domain, the product of the gene, the translation sequence as well as the FASTA files. The 
other database which was used for analysis was www.uniprot.org, which is a protein 
database. The accession number of each peptide hit was entered into each database, and 
based on the information, we were able to conduct gene ontology studies for each peptide hit, 
based on 3 parameters -biological function, molecular function and subcellular location. The 
gene ontology analysis (molecular function, biological function and subcellular location) of 
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each peptide hit was graphically represented based on abundance in the sample, using MS 
Excel.  
3.4. Results and Discussion 
3.4.1. Mass-spectrometric Analyses Of Schistosome Tail and Body samples 
 The data, specifically the gene accession numbers, obtained from the mass 
spectrometric analysis of the S. mansoni cercarial body and tail samples were analyzed using 
the parasitic genome database (www.gene.db) and it was found that there were 791 peptide 
hits in the cercarial tail and 645 peptide hits in the cercarial body. The cercarial tails and the 
cercarial bodies shared 491 proteins. 
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3.4.2. Results Of The Analysis Of The Proteomic Data Using Gene Ontology 
Using GO analysis, the peptide hits were divided into 3 main categories – 
molecular function i.e. the activities of the gene product at the molecular level; biological 
function i.e. a set of molecular events pertaining to the functioning of the specific gene 
product and finally cellular location i.e. the approximate location of the gene in the parts 
of the cell, both intercellular and extracellular spaces. Based on the analysis, S. mansoni 
cercarial tail peptide hits had 368 molecular functions, 324 biological functions and 134 
subcellular locations. The cercarial body had 315 molecular functions, 270 biological 
functions and  128 subcellular locations. 
In case of the S. mansoni cercarial tails (Figure number 3.4.B.), the top ten 
molecular functions were ATP binding,  metal ion binding, calcium ion binding, GTPase 
binding, RNA binding, GTP binding,  unfolded protein binding, actin binding, DNA 
binding, and magnesium ion binding. 
For the same sample (Figure number 3.4.C), the top ten biological functions were 
ubiquitin dependent protein catabolic process, signal transduction, tricarboxylic acid 
cycle, carbohydrate metabolic process, protein folding, cell redox homeostasis, cilium 
assembly, positive regulation of ATP dependent microtubule motor activity, plus end 
directed, proteasome mediated ubiquitin dependent protein catabolic process and 
transport along microtubule.  
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The top ten subcellular locations (Figure number 3.4.D), for the peptide hits to be 
abundantly present are cytoplasm, integral component of membrane, nucleus, membrane, 
cytoskeleton, cytosol, mitochondrion, mitochondrial inner membrane, multipass 
membrane protein  and mitochondrial respiratory chain complex 1.  
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In case of the S. mansoni cercarial bodies (Figure number 3.4.E) , the top ten 
molecular functions were ATP binding  calcium ion binding, metal ion binding GTP 
binding GTPase binding activity RNA binding unfolded protein binding DNA binding 
oxidoreductase activity and actin binding  
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For the same sample (Figure number 3.4.F), the top ten biological functions were 
mitochondrial electron transport protein finding tricarboxylic acid cycle, ubiquitin 
dependent protein catabolic process, ATP synthesis coupled electron transport, 
carbohydrate metabolic process, cell redox homeostasis, chaperone mediated protein 
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folding, cilium assembly and positive regulation of ATP dependent microtubule motor 
activity, plus end directed.   
 
From the figure number 3.4.G, the top ten subcellular locations for the peptide hits to be 
abundantly present are the cytoplasm , integral component of the membrane , nucleus , 
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membrane , cytoskeleton , cytosol , mitochondria , multi pass membrane protein cell  and 
mitochondrion inner membrane .  
ATP binding cassettes or ABCs are transport proteins which belong to a large 
family of membrane proteins, that interact selectively and non-covalently with ATP, and 
many of the functions include the transportation of diverse compounds such as peptides, 
metabolites, hormones, signaling molecules, immunomodulators, cholesterol, iron, drugs, 
toxins etc, [160-162]. Some of the proteins characterized in schistosomes include SmDR2 
and Sm MRP1. [160-162]. SmDR2 has been previously established as a schistosomal 
homolog of P-glycoprotein, the expression of which is upregulated in response to 
praziquantel concentration [161]. Similarly, SmMRP1, a schistosomal homolog of 
mammalian MRP1, was found to be upregulated in adult worms, when exposed to low 
concentrations of praziquantel [161] One of the theories behind the increasing 
praziquantel resistance in schistosomes may be due to the fact that the drug can bind to P-
glycoprotein (a subset of ABC proteins) and these multidrug resistance (MDR) associated 
proteins can be flushed out of the parasitic body [160-162]. In fact, schistosomal worm 
isolates from Egypt which demonstrated praziquantel resistance, displayed a very high 
expression of SmDR2  protein [161]. According to our data analysis, the number of 
peptide hits for ATP binding proteins in the cercarial tails is higher than that present in 
the cercarial bodies. Both SmDR2 and SmMRP1 could be potential targets for future drug 
design and therapy.  
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Table number 3.1. Table representing the comparison of the proteomic data from the 
peptide hits from the S. mansoni cercarial bodies versus the peptide hits from the 
S.mansoni cercarial tails, using Gene Ontology. 
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Calcium binding proteins or CaBPs are vital in the growth, development and 
maintenance of organisms.  From our proteomic analysis,  CaBPs are abundantly 
distributed in both the cercarial tails and the cercarial bodies. Based on literature review,  
a number of these proteins have been  characterized. In 1990, Sm20 was identified as a 
20-kilodalton functional calcium binding protein, expressed in S.mansoni schistosomules 
tegumental membranes and adult worms [163]. In 1992, SmE16 was characterized as a 
16-kilodalton calcium binding protein expressed in the S.mansoni eggs [164]. In 2002, 
SmTCTP (translationally controlled tumor protein) was isolated as a 23-kilodalton 
protein from all stages of the S.mansoni life cycle, the homologs of which had been 
previously found in Brugia malayi and Wuchereira bancrofti [165]. SmTCTP can bind to 
the heme portion of the host hemoglobin, as well as tubulin molecules, causing a release 
of histamine and secretion of interleukin-4 from basophil/mast cells, resulting in the 
development of allergic inflammation associated with schistosomiasis [165]. A proteomic 
analysis of S.mansoni cercarial secretions was conducted in 2005 and a number of 
proteins were identified, many of which were found to be responsible for the cercarial 
infection [95]. Some of the proteins were characterized as those involved in calcium 
binding, immune evasion (paramyosin), degradation of host skin barriers (proteases) and 
cytosolic proteins (heat shock proteins) [95]. In 2015, an 8-kilodalton intracellular 
calcium binding protein named SjCa8 was identified in S.japonicum cercariae and early 
stage schistosomules [166].This protein was found to have a significant inhibitory effect 
on the migration of macrophages, and potentially prevented the release of nitric oxide 
(NO) from the cells, thus allowing the somules from evading the host immune system, 
however the mode of action of SjCa8 is not completely known [166]. It is highly 
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probable that a homolog of this protein would be present in S.mansoni however, it has not 
been identified as of yet. In 2016, a family of calcium binding proteins were discovered 
in S.mansoni and these SmTAL proteins (tegumental allergen like proteins) were found to 
interact with praziquantel, however the exact mechanism of action is unknown [167]. Due 
to their abundant distribution, and their role in parasitic activity, calcium binding proteins 
can be considered as potential targets for the design of promising chemotherapeutic 
drugs.  
Metal binding proteins are distributed throughout the S.mansoni cercarial bodies, 
with more peptide hits identified in the cercarial tails (43%) compared to the cercarial 
bodies (35%). One example of a schistosomal metal binding protein which has been 
successfully characterized, is SmPCS or S.mansoni phytochelatins synthase (PCS), 
belonging to the papain family of cysteine proteases [67].This enzyme cleaves 
glutathione to release oligopeptides known as phytochelatins, which can scavenge and 
sequester toxic heavy metals leading to metallic detoxification [67]. SmPCS is found in 
plants, cyanobacteria, algae, ferns, fungi, nematodes but are absent in human[67]. The 
ability of SmPCS in regulating the availability of metal ions, thus contributing towards 
pathogen survival, makes it a potential target for designing antiparasitic drugs [67]. 
Another example of a  metal ion binding protein is SmCREB-binding protein (cAMP 
response element binding protein), which can activate gene transcription by interacting 
selectively and noncovalently with zinc ions. Based on their function, metal binding 
proteins are vital for the development and maintenance of the schistosomal life cycle.  
The fourth most abundant peptide in the S.mansoni cercarial body was identified 
as a low molecular weight Rab related GTP binding protein (SmRab), using proteomic 
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data analysis [168]. Once activated, these proteins are essential for membrane trafficking, 
vesicle formation, membrane fusion and vesicle movement along actin, tubulin networks 
[168]. RNA binding proteins such as Y-box binding proteins or YBPs have also been 
isolated and characterized in schistosomes [169]. Located within the cytoplasm of 
parasitic cells, SmYB1 is responsible for gene expression, translational regulation, 
transcriptional regulation, DNA repair, cellular proliferation, drug resistance ,stress 
response, mRNA processing and post translational gene regulation. [169]. All these 
above-mentioned proteins can be considered as potential targets for designing and 
manufacturing antischistosomal chemotherapeutic drugs.  
In the S.mansoni cercarial bodies, the top biological functions identified from the 
proteomic data analysis were mitochondrial electron transport, protein folding, 
tricarboxylic acid (TCA cycle), ubiquitin dependent protein catabolic process and ATP 
synthesis coupled electron transport. In the cercarial tails the top five biological functions 
were ubiquitin dependent protein catabolic process, signal transduction, TCA cycle, 
carbohydrate metabolism and finally protein folding. One of the top biological functions 
of the peptide hits in both cercarial bodies and cercarial tails is the tricarboxylic acid 
(TCA cycle). As mentioned before, the cercarial stage of S.mansoni relies on its glycogen 
store for its supply of energy. Once the glycogen store is exhausted, the parasite is unable 
to survive due to lack of  glycolytic activity. The process in which glycogen is converted 
to glucose is defined as glycogenolysis, in which glycogen is cleaved by glycogen 
phosphorylase to provide glucose -1- phosphate, which in turn is converted to glucose-6-
phosphate by phosphoglucomutase. The glucose-6-phosphate undergoes glycolysis to 
provide energy in the form of ATP, and this fuels the movement of the muscular cells of 
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the cercariae. The pyruvate is produced as a by-product of glycolysis, which is oxidized 
during the tricarboxylic acid cycle into carbon dioxide and water. The total number of 
ATP molecules produced during glycolysis is 8, and in the TCA cycle, is 24. These ATP 
molecules provide energy which in turn can make the cercariae hyperactive. The number 
of peptide hits involved in the TCA cycle are higher in the cercarial tails (15 hits) as 
compared to the cercarial bodies (12 hits), which explains the very high level of 
movement in the tails.  The number of peptide hits involved in the ubiquitin dependent 
protein catabolic process were found to be higher in S.mansoni cercarial tails (16 hits) as 
compared to cercarial bodies (11 hits). This biological process is responsible for the 
breakdown of a protein or a peptide by hydrolysis of the peptide bonds, caused by the 
covalent attachment of a ubiquitin group to the protein. The other top biological functions 
present in the cercarial tails were signal transduction conducted by protein kinases,  and 
carbohydrate metabolism. The biological functions can explain the hyperactivity of the 
cercariae, which in turn assist in identifying, infecting and penetrating the vertebrate host. 
In addition, since glycogenolysis and glycolysis occur in the cytoplasm of the cell, it 
makes sense that the top subcellular location for the peptide hits in both cercarial bodies 
and cercarial tails is the cytoplasm. 
3.5. Conclusion 
 
Schistosomiasis is a life threatening neglected tropical disease caused by 
schistosomes , second only to malaria responsible for the loss of 1.53 million disability-
adjusted life years (DALYs) as well as 280,000 deaths annually in sub-Saharan Africa alone 
[14-16]. According to  reports published by the World Health Organization (WHO), 220.8 
million people required preventive treatment in 2017, out of which more than 102.3 million 
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people were reported to be treated. Presently, praziquantel is the only drug which is used to 
treat patients, however in recent years, there has been a gradual increase in parasitic drug 
resistance [67]. Although a lot of scientific research is being carried out all over the world, 
with the sole aim of eliminating the disease, there is still a long way to go.  
The S.mansoni parasitic eggs are released in the excretory system by an infected 
patient, which then hatch in fresh water to form miracidia. The miracidia infect the first 
invertebrate vector—B. glabrata snails, within which they develop and are shed as highly 
motile cercariae—the most active and infectious stage of the parasitic life cycle.  The 
expansion and the contraction of the parasitic muscular system contributes towards its 
movement e.g. the diagonal muscles, longitudinal muscles and circular muscles in the 
cercarial body; striated muscles in the tail and longitudinal as well as circular muscles in the 
furcae  [27] . Other factors include  gravity, light, temperature, water turbulence and 
chemoattractant gradients of skin and blood of the host [154, 156, 157]. Once the cercariae 
penetrates into the human skin, the secretion of the acetabular glands occur in response to the 
host cues and chemical host signals, thus allowing the parasite to penetrate into the host skin 
[158, 159, 166]. Post infection host, the cercariae loses its tails and transforms into 
schistosomules which then proceed to migrate through the body’s lungs and portal 
circulatory system [166]. The somules develop into adult worms in the hepatic portal system, 
mate and lay eggs, thus leading to the symptoms of the disease in the patient. Since the 
cercarial tail plays a significant role in identifying and penetrating a potential mammalian 
host, this paper attempts  to present  a qualitative and quantitative proteomic analysis of 
cercarial tail proteins in detail, with the hope of identifying specific proteins as potential 
targets for designing chemotherapeutic drugs.  
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The world of proteomics allows large-scale experimental investigation of biological 
material, specifically focusing on the proteins as well as an conducting an in-depth study of 
cellular systems [94]. The popularity and advances in this field is largely due to 
improvements in mass spectrometry, the development of databases and the creation of new 
computer algorithms [94]. In fact, mass spectrometry is an indispensable tool for this field of 
study. In case of schistosomiasis, the genomes of S. japonicum, S. mansoni and that of the 
intermediate snail host, Bioamphalaria glabrata, have been  extensively documented [22, 66, 
95, 140]. A vast transcriptome database containing resources for peptide sequences for S. 
mansoni was published in 2003, thus providing clues for research in parasite cell biology 
[141]. In 2005, a proteomic analysis of cercarial secretions was carried out and a number of 
proteins were identified, which were found to be responsible for the spread of the disease 
[95]. Some of the proteins were calcium associated proteins (e.g. calcium binding, calcium 
regulation, calcium activation), immune evasion (e.g. paramyosin), degradation of the host 
skin barrier (e.g. proteases) and heat shock proteins (e.g. cytosolic proteins, heat shock 
proteins) [95].For our paper, we carried out a mass spectrometric analysis of the proteins 
isolated and purified from the cercarial tails as well as the cercarial bodies. Using the 
parasitic genome database (www.gene.db) it revealed the presence of  791 peptide hits in the 
cercarial tail and 645 peptide hits in the cercarial body, with an overlap of 491 proteins.  
With the help of gene ontology (GO) analysis, the peptide hits were divided into three 
groups – those based on molecular function , those based on biological function and 
finally those based on cellular location. Based on the analysis, S. mansoni cercarial tail 
peptide hits had 368 molecular functions, 324 biological functions and 134 subcellular 
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locations. In comparison, the peptide hits in the he cercarial body had 315 molecular 
functions, 270 biological functions and  128 subcellular locations.  
For S. mansoni cercarial tails, the top molecular functions were ATP binding,  
metal ion binding, calcium ion binding, GTPase binding, RNA binding, GTP binding, 
unfolded protein binding, actin binding, DNA binding, and magnesium ion binding. In 
case of the S. mansoni cercarial bodies, the top ten molecular functions were ATP 
binding calcium ion binding, metal ion binding GTP binding GTPase binding activity 
RNA binding unfolded protein binding DNA binding oxidoreductase activity and actin 
binding . In cercarial tails, the top ten biological functions were ubiquitin dependent 
protein catabolic process, signal transduction, tricarboxylic acid cycle, carbohydrate 
metabolic process, protein folding, cell redox homeostasis, cilium assembly, positive 
regulation of ATP dependent microtubule motor activity, plus end directed, proteasome 
mediated ubiquitin dependent protein catabolic process and transport along microtubule. 
On the other hand, for cercarial bodies, the top ten biological functions were 
mitochondrial electron transport protein finding tricarboxylic acid cycle, ubiquitin 
dependent protein catabolic process, ATP synthesis coupled electron transport, 
carbohydrate metabolic process, cell redox homeostasis, chaperone mediated protein 
folding, cilium assembly and positive regulation of ATP dependent microtubule motor 
activity, plus end directed. The fact that more ATP binding peptide hits were identified  
in the cercarial tails than in the bodies is  significant , because this result can explain the 
energy involved in the hyperactivity of the tails. The top biological functions of the 
peptide hits in both cercarial bodies and cercarial tails is the tricarboxylic acid (TCA 
cycle), followed by ubiquitin dependent protein catabolic process, and protein folding. 
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The entire responsibility of localizing and penetrating a mammalian host is undertaken by 
the cercarial tails. The free-living, non-feeding cercariae swim tail-first, depending on its 
glycogen source for bursts of energy. The parasites continue to seek a suitable vertebrate 
mammalian host, until the cercarial glycogen source is completely exhausted. The 
process in which glycogen is broken down to produce glucose is known as 
glycogenolysis. Since cercariae are incapable of carrying out glycolysis on their own, the 
depleting of glycogen ends up killing the parasite. These particular proteins can be 
considered as potential chemotherapeutic drug targets, for designing future 
antischistosomal agents. Other ATP binding proteins could include specific transport 
proteins such as SmDR2 and SmMRP1 that interact with ATP, and some of the functions 
include the transportation of  peptides, metabolites, hormones, signaling molecules, 
immunomodulators, cholesterol, iron, drugs, toxins etc, [160-162].  
In the cercarial tails,  the peptide hits are abundantly distributed in cytoplasm, 
integral component of membrane, nucleus, membrane, cytoskeleton, cytosol, 
mitochondrion, mitochondrial inner membrane, multipass membrane protein  and 
mitochondrial respiratory chain complex 1 whereas in cercarial bodies, the peptide hits 
are in the cytoplasm , integral component of the membrane,  nucleus , membrane , 
cytoskeleton , cytosol , mitochondria , multi pass membrane protein , cell and 
mitochondrion inner membrane . Since glycogenolysis and glycolysis occur in the 
cytoplasm of the cell, it makes sense that the top subcellular location for the peptide hits 
in both cercarial bodies and cercarial tails is the cytoplasm.  
Based on gene ontology analysis, calcium binding proteins or CaBPs, metal 
binding proteins and GTP binding proteins are always distributed throughout the cercarial 
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system, and they play essential roles in the overall development and growth of the 
parasite. These peptide hits could be studied further as possible targets for manufacturing 
antiparasitic drugs. If the movement of cercariae can be prevented or slowed down, this 
could stop them from infecting mammalian hosts, thus decreasing the spread of 
schistosomiasis. 
Additional  analysis of the proteomic data was conducted by our colleagues at the 
Genome Informatics Facility (GIF) of Iowa State University, using a software called 
MetaboAnalyst 4.0 to process metabolomic data,  provide visualization of data, statistical 
analysis and functional interpretation [170-172]. NCBI-Gene IDs for all the proteins that 
were significant (P value <0.1) were mapped to the Kyoto Encyclopedia of Genes and 
Genomes or KEGG pathway, which is an integrated comprehensive database resource 
developed for the biological interpretation of large-scale datasets as well as the molecular 
functions stored as a functional ortholog of genes and proteins. (Data  not shown). 
In conclusion, we have attempted to present a completed qualitative and quantitative 
proteomic analysis as well as a thorough comparison of the peptide hits in the S. mansoni 
cercarial tail versus those in the  cercarial bodies.  
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CHAPTER 4 : A MINIATURIZED SCREEN OF A SCHISTOSOMA MANSONI 
SEROTONERGIC G PROTEIN-COUPLED RECEPTOR IDENTIFIES NOVEL 
CLASSES OF PARASITE-SELECTIVE INHIBITORS 
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4.1. Summary 
 
Schistosomiasis is the second most dangerous neglected tropical disease, after malaria 
and is caused by water borne parasitic worms called schistosomes. S.mansoni is responsible 
for causing intestinal schistosomiasis, which is presently prevalent in more than 149 
countries. According to a report filed by the World Health Organization (WHO) in 2016, 
schistosomiasis is responsible for approximately 200,000 deaths per year in sub-Saharan 
Africa alone. The lone drug responsible for treating patients is praziquantel, however with 
the recent reports of increasing drug resistance, it is highly important that more effective 
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drugs be designed and manufactured. New generation anti schistosomal drugs are difficult to 
create due to the lack of library screening of flatworm G-protein coupled receptors or 
GPCRs. This paper presents a novel, non-destructive and highly efficient method of 
pharmacological profiling of S.mansoni GPCRs. Serotonin or 5-hydroxy tyrosine (5-HT) is a  
ligand which binds to Sm5HTR , leading to receptor activation, causing an increase in the 
concentration of adenylyl cyclase enzyme, which in turn causes an increase in the 
concentration of cAMP. This increased cAMP can bind to a luciferase construct resulting in 
enhanced luminescence. A number of drugs were tested using this experiment and it was 
determined that selective inhibition of Sm5HTR was caused by alfuzosin, orphenadrine, 
atomoxetine and rotundine, of which the latter was found to be most sensitive.  My 
contribution towards the paper was in the Materials and Methods section, where I isolated 
Schistosoma mansoni cercariae from infected Bioamphalaria glabrata snails. I transformed 
the cercariae into schistosomules, purified them and tested a set of chemical compounds of 
varying concentrations on them, to study their motility under the effect of the drugs. I also 
carried out the euthanization of the Schistosoma mansoni infected Swiss Webster mice, and 
assisted Dr. John Chan in isolating and purifying the adult worms from the mesenteric veins 
of the mice. 
4.2. Materials and Methods 
4.2.1. Experimental Animals  
The NIAID Schistosomiasis Resource Center of the Biomedical Research Institute 
(BRI, Rockville, MD) provided the S. mansoni infected Biomphalaria glabrata snails, 
through NIH-NIAID Contract HHSN272201000005I for distribution through BEI Resources 
(Catalogue number #NR-21961). The infected snails were fed fresh lettuce leaves and 
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maintained at 26°C-28°C in charcoal-filtered, aerated water. Swiss Webster mice exposed to 
Schistosoma mansoni cercaria at 5-7 weeks old were obtained from BEI Resources 
(Catalogue number # NR-34792) and maintained at the laboratories animal resources (LAR) 
facilities at Iowa State University College of Veterinary Medicine. The protocol of animal 
work was approved by the LAR facility. 
4.2.2. Cercarial Shedding of Snails  
In a 250 ml. glass beaker containing 40 ml. of charcoal-filtered, aerated water, 
approximately 30-40 S. mansoni infected B. glabrata snails were placed. The water was 
enough to cover the snails. The cercariae were shed from the snails, by exposing the snails to 
a 120V 60W light bulb for up to 2 hours. The water from each beaker was filtered through a 
glass funnel (VWR catalog number #89428-960) containing a 47-uM pore sized metal screen 
(VWR catalog number # 89428-966). Once the cercariae were transferred to a pre-chilled 50 
ml. falcon tube placed on ice, the cercariae were allowed to settle at the bottom of the falcon 
tube. The supernatant was discarded, and 5-10 ml. solution with the pellet was left at the 
bottom of the tube. 
4.2.3. Transformation of Cercariae To Schistosomules, Separation and Collection of 
The Somules  
In order to produce schistosomules the cercarial solution was vortexed 6-7 times for 1 
minute followed by 1 minute on ice thus manually separating the tails from the cercarial 
bodies. Percoll density gradient centrifugation was then used to separate the tails from the 
cercarial bodies.  40 ml. of a 60% Percoll solution were prepared from 24 ml. percoll (Fisher 
Scientific catalog number # 45001754), 4 ml. of 10X MEM Vitamin solution (Life 
Technologies catalog number #11430030), 1 ml of 85% (weight/volume) sodium chloride in 
1M HEPES, 1.5 ml. of 100X antibacterial-antimycotic solution (Thermo Fisher Scientific 
catalog number #15240062) and 9.5 ml. of molecular grade water.  The vortexed cercarial 
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solution was pipetted on top of the percoll gradient solution. Centrifugation was carried out 
at 900g for 45 minutes at 4°CPost centrifugation, the tails accumulated at the top of the 
percoll were discarded, and the somules collected as a prominent pellet at the bottom of the 
tube. The somules were washed once with sterile Dulbecco’s phosphate buffered solution 
(DPBS) (Thermo Fisher Scientific catalog number #14190250) and centrifuged at 20 minutes 
at 500g at 4°C. The recovered pellet containing the purified somules was resuspended in 
freshly made, sterile Basch media, and incubated at 37°C , 5% CO2 overnight in an 
incubator.  
4.2.4. Composition of Basch Media 
 The protocol for Basch media was provided by the Caffrey lab at the Skaggs School 
of Pharmacy and Pharmaceutical Science, University of California San Diego, USA. The 
media was made in the following way: - 9.23 gms. of MEM with Earl’s Salt, without L-
Glutamate, phenol red, sodium bicarbonate (JRC catalog number # 56-119-000) was 
dissolved in 1L of distilled water, followed by 1000 mgms. of glucose (Fisher Scientific 
catalog number # D-16-3) and 2400 mgms. of HEPES (Fisher Scientific catalog number # 
6003H). 1000 milligrams of lactalbumin hydrolysate (BRL Catalog number # 11800-025) 
was added to the mixture and it was allowed to dissolve for 15-20 minutes on a magnetic 
shaker. Once dissolved, 2.2 gms of sodium bicarbonate (Corning Cellgro catalog number # 
90-009-PB) was added to the media. 500 uls. of 1 mM hypoxanthine (Sigma catalog number 
# H-9377), 500 uls. of 1 mM hydrocortisone (Sigma catalog number # H-0888), 500 uls. of 1 
mM triiodothyronine (Sigma catalog number # T-5516) and 900 uls. of bovine pancreas 
insulin (Sigma catalog number # I-5500) was added to the mixture, after which the pH was 
adjusted to 7.3-7.4. 50 uls. of 1X Schneider’s media (Invitrogen catalog number # 11720-
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034) and 5 ml of 100X MEM Vitamins (Invitrogen catalog number # 11120-052) were added 
and the pH was again calibrated to 7.3-7.4. The entire media was filter sterilized and to the 
sterile Basch media, 500 uls. of Penicillin-Streptomycin and 50 uls. of 5% re filtered, heat 
inactivated fetal bovine serum (JRS catalog number # 43640-100) was added. Aliquots of 50 
ml were made and stored at 4°C. 
4.2.5. Testing Drugs on Schistosomules In A 24 Welled Plate 
Freshly isolated S. mansoni somules (approximately 200 somules per 500µls /well) were 
added to 6 welled cell culture, non-pyrogenic, polystyrene plates (Corning Incorporated 
catalog number #3506) containing Basch Media To the somules, a 1:1 dilution of the drugs 
(diluted in Basch media) of varying concentrations per well i.e. 0.1 uM, 1.0 uM, 5 uM, 10 
uM, 50 uM and 100 uM, were added and were incubated for 30 minutes at 37°C, 5% CO2. 
Motility of the somules were recorded for 5 minutes, at the rate of 10 somules per view 
through a 10X objective lens of a compound microscope (Nikon Eclipse TS100), equipped 
with a digital camera ( Zoom Nikkor ED Glass 5.0 Mega pixels 8X zoom, electric view 
finder).  Serotonin hydrochloride (Sigma Aldrich catalog number # H9523) was used as a 
positive myo-excitatory control as it can stimulate movement and carbamoyl choline chloride 
(Sigma Aldrich catalog number # C4382) was used as negative control, as it can inhibit 
movement. Both products were used at the following concentrations: - 0.1uM, 1uM, 5uM, 
10uM and 100uM.  The videos were uploaded to Iowa State University’s Cybox, and they 
were analyzed by Dr. John Chan. The WrMTrck plugin of Image J was used to quantify the 
effect of the drug on the somule’s movement.   
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4.2.6. Isolation of Adult Schistosoma mansoni Worms from Swiss Webster Mice  
The mice exposed to Schistosoma mansoni cercaria were euthanized at 6-8 weeks 
post infection. The mice were administered CO2 in a carbon dioxide chamber, and then 
sacrificed by cervical dislocation. The mice were perfused with 25mM of sodium citrate 
solution (Fisher Scientific catalogue number S279-500) and the adult worms were harvested 
from the mesenteric veins of the mice. The worms were incubated at 37°C, 5 % Co2 
overnight, and the motility of the adult worms were analyzed by Dr. John Chan.  
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CHAPTER 5 : PHARMACOLOGICAL PROFILING AN ABUNDANTLY 
EXPRESSED SCHISTOSOME SEROTONERGIC GPCR IDENTIFIES 
NUCIFERINE AS A POTENT ANTAGONIST 
 
Modified from a manuscript published in International Journal for Parasitology : Drugs and 
Drug Resistance. (2016). 
John D. Chan a, Sreemoyee Acharya b, Timothy A. Day b, Jonathan S. Marchant a,c. 
a Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota, 55455, 
USA. 
b Department of Biomedical Sciences, Iowa State University, Ames, Iowa, 50011, USA. 
c Stem Cell Institute, University of Minnesota, Minneapolis, Minnesota, 55455, USA. 
5.1. Summary 
 
Schistosomiasis is the second most dangerous neglected tropical disease, after malaria 
and is caused by water borne parasitic worms called schistosomes. S.mansoni is responsible 
for causing intestinal schistosomiasis, which is presently prevalent in more than 149 
countries. According to a report filed by the World Health Organization (WHO) in 2016, 
schistosomiasis is responsible for approximately 200,000 deaths per year in sub-Saharan 
Africa alone. The lone drug responsible for treating patients is praziquantel, however with 
the recent reports of increasing drug resistance, it is highly important that more effective 
drugs be designed and manufactured. Potential anti schistosomal drugs were screened using a 
novel cAMP biosensor assay, and four structurally related aporphines – nuciferine, D-
glaucine, boldine, bulbocalpine- were found to be highly effective in preventing motility in 
adult worms. Of the 4 drugs, nuciferine was found to be most effective.   Like the previous 
published paper, my contribution towards this paper was in the Materials and Methods 
section, where I isolated Schistosoma mansoni cercariae from infected Bioamphalaria 
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glabrata snails. I transformed the cercariae into schistosomules, purified them and tested a 
set of chemical compounds of varying concentrations on them, to study their motility under 
the effect of the drugs. I also carried out the euthanization of the Schistosoma mansoni 
infected Swiss Webster mice, and assisted Dr. John Chan in isolating and purifying the adult 
worms from the mesenteric veins of the mice. 
5.2. Materials and Methods 
 
5.2.1. Experimental Animals 
 
The NIAID Schistosomiasis Resource Center of the Biomedical Research Institute 
(BRI, Rockville, MD) provided the S. mansoni infected Biomphalaria glabrata snails, 
through NIH-NIAID Contract HHSN272201000005I for distribution through BEI Resources 
(Catalogue number #NR-21961). The infected snails were fed fresh lettuce leaves and 
maintained at 26°C-28°C in charcoal-filtered, aerated water. Swiss Webster mice exposed to 
Schistosoma mansoni cercaria at 5-7 weeks old were obtained from BEI Resources 
(Catalogue number # NR-34792) and maintained at the laboratories animal resources (LAR) 
facilities at Iowa State University College of Veterinary Medicine. The protocol of animal 
work was approved by the LAR facility. 
5.2.2. Cercarial Shedding of Snails  
In a 250 ml. glass beaker containing 40 ml. of charcoal-filtered, aerated water, 
approximately 30-40 S. mansoni infected B. glabrata snails were placed. The water was 
enough to cover the snails. The cercariae were shed from the snails, by exposing the snails to 
a 120V 60W light bulb for up to 2 hours. The water from each beaker was filtered through a 
glass funnel (VWR catalog number #89428-960) containing a 47-uM pore sized metal screen 
(VWR catalog number # 89428-966). Once the cercariae were transferred to a pre-chilled 50 
ml. falcon tube placed on ice, the cercariae were allowed to settle at the bottom of the falcon 
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tube. The supernatant was discarded, and 5-10 ml. solution with the pellet was left at the 
bottom of the tube. 
5.2.3. Transformation of Cercariae To Schistosomules, Separation and Collection of 
The Somules  
In order to produce schistosomules the cercarial solution was vortexed 6-7 times for 1 
minute followed by 1 minute on ice thus manually separating the tails from the cercarial 
bodies. Percoll density gradient centrifugation was then used to separate the tails from the 
cercarial bodies.  40 ml. of a 60% Percoll solution were prepared from 24 ml. percoll (Fisher 
Scientific catalog number # 45001754), 4 ml. of 10X MEM Vitamin solution (Life 
Technologies catalog number #11430030), 1 ml of 85% (weight/volume) sodium chloride in 
1M HEPES, 1.5 ml. of 100X antibacterial-antimycotic solution (Thermo Fisher Scientific 
catalog number #15240062) and 9.5 ml. of molecular grade water.  The vortexed cercarial 
solution was pipetted on top of the percoll gradient solution. Centrifugation was carried out 
at 900g for 45 minutes at 4°C. 
Post centrifugation, the tails accumulated at the top of the percoll were discarded, and 
the somules collected as a prominent pellet at the bottom of the tube. The somules were 
washed once with sterile Dulbecco’s phosphate buffered solution (DPBS) (Thermo Fisher 
Scientific catalog number #14190250) and centrifuged at 20 minutes at 500g at 4°C. The 
recovered pellet containing the purified somules was resuspended in freshly made, sterile 
Basch media, and incubated at 37°C , 5% CO2 overnight in an incubator.  
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5.2.4. Composition Of Basch Media  
The protocol for Basch media was provided by the Caffrey lab at the Skaggs School of 
Pharmacy and Pharmaceutical Science, University of California San Diego, USA. The media 
was made in the following way: - 9.23 gms. of MEM with Earl’s Salt, without L-Glutamate, 
phenol red, sodium bicarbonate (JRC catalog number # 56-119-000) was dissolved in 1L of 
distilled water, followed by 1000 mgms. of glucose (Fisher Scientific catalog number # D-
16-3) and 2400 mgms. of HEPES (Fisher Scientific catalog number # 6003H). 1000 
milligrams of lactalbumin hydrolysate (BRL Catalog number # 11800-025) was added to the 
mixture and it was allowed to dissolve for 15-20 minutes on a magnetic shaker. Once 
dissolved, 2.2 gms of sodium bicarbonate (Corning Cellgro catalog number # 90-009-PB) 
was added to the media. 500 uls. of 1 mM hypoxanthine (Sigma catalog number # H-9377), 
500 uls. of 1 mM hydrocortisone (Sigma catalog number # H-0888), 500 uls. of 1 mM 
triiodothyronine (Sigma catalog number # T-5516) and 900 uls. of bovine pancreas insulin 
(Sigma catalog number # I-5500) was added to the mixture, after which the pH was adjusted 
to 7.3-7.4. 50 uls. of 1X Schneider’s media (Invitrogen catalog number # 11720-034) and 5 
ml of 100X MEM Vitamins (Invitrogen catalog number # 11120-052) were added and the 
pH was again calibrated to 7.3-7.4. The entire media was filter sterilized and to the sterile 
Basch media, 500 uls. of Penicillin-Streptomycin and 50 uls. of 5% re filtered, heat 
inactivated fetal bovine serum (JRS catalog number # 43640-100) was added. Aliquots of 50 
ml were made and stored at 4°C. 
5.2.5. Testing Drugs on Schistosomules  
In A 24 Welled PlateFreshly isolated S. mansoni somules (approximately 200 
somules per 500µls /well) were added to 6 welled cell culture, non-pyrogenic, polystyrene 
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plates (Corning Incorporated catalog number #3506) containing Basch Media To the 
somules, a 1:1 dilution of the drugs (diluted in Basch media) of varying concentrations per 
well i.e. 0.1 uM, 1.0 uM, 5 uM, 10 uM, 50 uM and 100 uM, were added and were incubated 
for 30 minutes at 37°C, 5% CO2. Motility of the somules were recorded for 5 minutes, at the 
rate of 10 somules per view through a 10X objective lens of a compound microscope (Nikon 
Eclipse TS100), equipped with a digital camera ( Zoom Nikkor ED Glass 5.0 Mega pixels 8X 
zoom, electric view finder).  Serotonin hydrochloride (Sigma Aldrich catalog number # 
H9523) was used as a positive myo-excitatory control as it can stimulate movement and 
carbamoyl choline chloride (Sigma Aldrich catalog number # C4382) was used as negative 
control, as it can inhibit movement. Both products were used at the following concentrations: 
- 0.1uM, 1uM, 5uM, 10uM and 100uM.  The videos were uploaded to Iowa State 
University’s Cybox, and they were analyzed by Dr. John Chan. The WrMTrck plugin of 
Image J was used to quantify the effect of the drug on the somule’s movement.  
5.2.6. Isolation of Adult Schistosoma mansoni Worms from Swiss Webster Mice  
The mice exposed to Schistosoma mansoni cercaria were euthanized at 6-8 weeks 
post infection. The mice were administered CO2 in a carbon dioxide chamber, and then 
sacrificed by cervical dislocation. The mice were perfused with 25mM of sodium citrate 
solution (Fisher Scientific catalogue number S279-500) and the adult worms were harvested 
from the mesenteric veins of the mice. The worms were incubated at 37°C, 5 % Co2 
overnight, and the motility of the adult worms were analyzed by Dr. John Chan. 
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CHAPTER 7 : GENERAL CONCLUSION 
 
Schistosomiasis is an endemic neglected tropical disease (NTD), second only to 
malaria as the most devastating parasitic disease in the world [8-11].According to the reports 
filed by World Health Organization (WHO) and Centers for Disease Control and Prevention 
(CDC), more than one billion people, mostly from low-income and middle-income 
populations, are affected by NTDs in at least 149 countries [1-6]. The fresh water parasitic 
worm belonging to the phyla platyhelminthes, Schistosoma mansoni causes intestinal 
schistosomiasis, and is responsible for high morbidity and mortality rates [9]. The lone drug 
responsible for treating this disease is praziquantel, however due to several problems 
associated with the usage of the drug such as its effectiveness only against adult worms, as 
well as emerging reports of drug resistance, it is extremely important to look into more 
efficient chemotherapeutic agents to treat schistosomiasis [66].  
The transmission of schistosomiasis largely depends on the motility of the parasite at 
different stages of its life cycle. When infected people expel schistosomal eggs into the fresh 
water through their excretory systems, the eggs hatch to produce ciliated and highly active 
miracidia.  Once the miracidia penetrates the intermediate invertebrate snail host, it 
undergoes asexual reproduction to produce sporocysts, which eventually differentiates into 
free swimming, non-feeding, highly infectious larval forms called cercariae [22, 24, 173]. 
These highly mobile parasites survive in water for approximately 2 days or 48 hours, relying 
on its store of glycogen to provide energy [151]. In fact, the cercarial tails are found to 
possess more glycogen than cercarial bodies, and the glycogen undergoes glycogenolysis to 
provide glucose which then proceeds to produce ATP via glycolysis [151]. The main purpose 
of the cercariae it to seek out a suitable mammalian host to infect, thus bridging the gap 
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between the intermediate host and the definitive host [4, 28]. Once the human host is 
infected, the cercariae sheds its tail and transforms into schistosomules, which then travel 
through the circulatory system to the superior mesenteric channels, where they proceed to 
mature into adult worms [4]. The adult worms mate and produce a large quantity of eggs 
(100-300 eggs/day), most of which are excreted through the host’s excretory system, and the 
remaining are permanently lodged within the liver and small intestine of the human body [4, 
39, 96]. The pathology of the disease is caused by the response of the host’s immune system 
to the eggs, and not just by the presence of the juvenile or adult parasitic worms in the body 
[4, 8, 13, 24, 40]. Schistosomiasis relies on the motility of the cercariae before human 
infection, and the movement of the schistosomules through the human body post-infection. 
For my doctoral dissertation, I have focused on the motility aspect of the S.mansoni worms 
pre and post infection, with the hope of identifying possible targets for designing potential 
chemotherapeutic agents, to prevent schistosomal movement, thus inhibiting the spread of 
the disease.  
My research is broadly divided into two categories— the first part of my dissertation 
deals with the development of a sensitive, simple, cheap and easily accessible biological 
assay to study the movement of S.mansoni somules as they travel through the host circulatory 
system. In recent times, microfluidic devices or “Lab-on-a-chip” technology have become 
increasingly popular in biological applications such as electrophysiology, pharmaceutical 
analysis, screening of drugs, analysis of cells and cellular materials, separation and screening 
of biomolecules, diagnostics, and tissue engineering  [92]. In fact, microfluidics has been 
used  to successfully study the movement of C. elegans [93, 120]. This assay has many 
significant advantages such as the integration of an entire lab on a single small chip; reduced 
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chemical wastage, lowered costs, reduced reaction times, faster screening of novel 
compounds, simpler, quicker, portable, affordable manufacture as well as the ability to study 
several experiments simultaneously  [96, 119, 137]. Here we have demonstrated specially 
manufactured microfluidic chips to study the movement and behavior of S. mansoni somules 
as they move through the sinusoidal channels designed on the chips, thus mimicking the host 
circulatory system. To quantitatively analyze somule motility, the Njus-Pandey research 
group at Iowa State University created a custom software program using two parameters (1) 
centroid distance to measure the activity of the somule at one point, and (2) track distance to 
measure the distance covered by the worm from one position to the other. Of the 11 chosen 
neuropeptides, 3 peptides were chosen to study the effect of each NP on somule motility. The 
3 peptides were AFVRL-amide, GFVRI-amide and YIRF-amide.  
With the first set of experiments conducted in 6 welled plates, it was observed that the 
motility of the somules increased with an increase in concentration of GFVRI-amide as well 
as AFVRL-amide and there was a substantial decrease in somule motility with an increase in 
the concentration of YIRF-amide. The results we obtained from the GFVRI-amide treated 
somules did not correspond with previously published data, which had stated that GFVRI-
amide has an inhibitory effect on S. mansoni adults and somules [80]. In addition, the data 
we obtained from the YIRF-treated somules did not match with those published in 2011, 
which stated that the peptide had an inhibitory effect on the worms [80]. However our results 
did agree with those published earlier in 1997 by Day et al, which  suggested that YIRF-
amide had a myoexcitatory effect in somules [115].  
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In the second state of experiments, we introduced the drug treated somules to 
microfluidic channels, and the movement was recorded for 5 minutes. Using Dr. Njus’ 
custom software program, the video recordings were analyzed, and it was confirmed that the 
schistosomules treated with 100µM of AFVRL-amide displayed maximum centroid distance 
and those treated with 100µM of GFVRI- amide displayed minimum centroid distance, when 
compared to the controls. In other words, AFVRL-amide caused the worms to undergo high 
levels of contraction and expansion at one point, whereas GFVRI- amide caused the somules 
to demonstrate minimum expansion and contraction. This result corresponds with the data 
published by McVeigh et al. in 2011 [80].  
On the other hand, somules treated with 100µM of YIRF-amide demonstrated the 
maximum track distance i.e. these schistosomules covered the maximum distance from one 
point to the second point. The somules treated with 100µM of GFVRI-amide demonstrated 
the least track distance i.e. the schistosomules covered minimum distance between two 
points. These results introduced another novel hypothesis i.e. contractile activity of worms 
was inversely proportional to directional motility of the worms. In other words, the more a 
parasite moves at one point, less is the distance it can travel. To prove this hypothesis, we 
tested somules with increasing concentrations of 5-HT and it was observed that centroid 
distance of the somules increased whereas the track distance decreased. This conclusively 
proves that contractile activity was inversely proportional to directional motility. It was 
proposed that the hyperactivity of the 5-HT treated somules caused a depletion in the energy 
stores, and this lack of energy prevented the somule from performing other activities, like 
migration. So, although the viability of the somule is dependent upon 5-HT, exposure to 
higher concentrations of 5-HT would destroy the somule.  
 
155 
In order to improve the microfluidic chip, it was of great importance to choose a 
suitable media, through which the schistosomules could move ahead easily, with minimum 
resistance. Of all the different types of media tested, we believe that collagen was the ideal 
media to use in microfluidic assays. Although this microfluidic assay seems promising for 
future research, it is not a perfect device, and requires improvement. But we believe it holds 
potential for studying the movement of parasites with ease and without the expenditure of too 
much money.  
The second part of my dissertation deals with the qualitative and quantitative 
proteomic analysis of the cercarial tails and  cercarial bodies. The world of proteomics allows 
large-scale experimental analysis of proteins of a cell line, tissue or organism as well as an 
in-depth study of cellular systems [94]. The popularity and advances in this field is largely 
due to improvements in mass spectrometry, the development of databases and the creation of 
new computer algorithms [94]. For the field of schistosomiasis, the genomes of S. japonicum, 
S. mansoni and that of the intermediate snail host, Bioamphalaria glabrata, have been 
analyzed extensively and documented [22, 66, 95, 140]. A vast transcriptome database 
containing resources for peptide sequences for S. mansoni was published in 2003, thus 
providing clues for research in parasite cell biology [141]. Since the cercarial tail plays a 
significant role in identifying and penetrating a host, we aimed to investigate and analyze 
cercarial tail proteins in detail, with the hope of identifying specific proteins as potential 
targets for designing chemotherapeutic drugs.  
There are several factors responsible for the hyperactivity of cercarial tails e.g. the 
presence of diagonal muscles, longitudinal muscles and circular muscles in the cercarial 
body; striated muscles in the tail and longitudinal as well as circular muscles in the furcae 
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[27] . Other factors include  gravity, light, temperature, water turbulence and chemoattractant 
gradients of skin and blood of the host [154, 156, 157]. Once the cercariae penetrates into the 
human skin, the secretion of the acetabular glands occur in response to the host cues and 
chemical host signals, thus allowing the parasite to penetrate into the host skin [158, 159]. 
Once inside the host, the cercariae transform into schistosomules by the removal of the 
cercarial tails. The somules then travel through the portal system, pulmonary system and the 
hepatic portal system of the host body, eventually developing into adult worms and lay eggs 
[166]. The symptoms of the disease are a result of the accumulation of the parasitic eggs 
within the host’s internal organs.  
Mass spectrometric analysis of the proteins isolated and purified from the cercarial 
tails as well as the cercarial bodies, using the parasitic genome database (www.gene.db) 
revealed the presence of 791 peptide hits in the cercarial tail and 645 peptide hits in the 
cercarial body, with an overlap of 491 proteins.  With the help of gene ontology (GO) 
analysis, the peptide hits were divided into three primary groups – those based on 
molecular function , those based on biological function and finally those based on 
cellular location. The peptide hits in the cercarial tail had 368 molecular functions, 324 
biological functions and 134 subcellular locations, whereas those in the cercarial body 
had 315 molecular functions, 270 biological functions and 128 subcellular locations. For 
the cercarial tails the top  molecular functions were ATP binding , metal ion binding and 
calcium ion binding ; the top biological functions were ubiquitin dependent protein 
catabolic process, signal transduction and tricarboxylic acid cycle and the top subcellular 
locations for the peptide hits were in the cytoplasm , the integral component of the 
membrane , and the nucleus. In the case of the cercarial bodies, the top molecular 
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functions were  ATP binding, calcium ion binding and metal ion binding ; the top 
biological functions were mitochondrial electron transport, protein finding, and 
tricarboxylic acid cycle and the top ten subcellular locations for the peptide hits were in 
the cytoplasm , the integral component of the membrane and the nucleus. The molecular 
functions of the peptide hits in both the tails and the bodies i.e. ATP, metal and calcium 
binding—explained the aggressive activity of the cercariae pre-infection. In fact, the 
presence of more ATP binding peptide hits in the tail when compared to those present in 
the body is a significant result, because the tails are more active than the bodies 
especially since the entire responsibility of identifying and penetrating a mammalian host 
is undertaken by the cercarial tails.  
One of the top biological functions of the peptide hits in both cercarial bodies and 
cercarial tails is the tricarboxylic acid (TCA cycle). As mentioned before the cercarial 
stage of S.mansoni relies on its glycogen store for its supply of energy. Once the 
glycogen store is exhausted, the parasite is unable to survive due to lack of any glycolytic 
activity. The process in which glycogen is converted to glucose is defined as 
glycogenolysis, in which glycogen is cleaved by glycogen phosphorylase to provide 
glucose -1- phosphate, which in turn is converted to glucose-6-phosphate by 
phosphoglucomutase. The glucose-6-phosphate undergoes glycolysis to provide energy in 
the form of ATP, and this fuels the movement of the muscular cells of the cercariae. The 
pyruvate is produced as a by-product of glycolysis, which is oxidized during the 
tricarboxylic acid cycle into carbon dioxide and water. The total number of ATP 
molecules produced during glycolysis is 8, and in the TCA cycle, is 24. These ATP 
molecules provide energy which in turn can make the cercariae hyperactive. Since 
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glycogenolysis and glycolysis occur in the cytoplasm of the cell, it makes sense that the 
top subcellular location for the peptide hits in both cercarial bodies and cercarial tails is 
the cytoplasm. In summary, we attempted to present a completed proteomic analysis and an 
extensive comparison of the S. mansoni cercarial tails and cercarial bodies.  
Schistosomiasis is a debilitating disease which is responsible for the loss of 1.53 
million disability-adjusted life years (DALYs) and up to 280,000 deaths annually in sub-
Saharan Africa alone [14-16]. It affects people from all stages of life---from a child to a 
senior citizen. Female urogenital schistosomiasis caused by S. haematobium which could 
lead to cysts or even cervical cancer, is a field which requires a lot of attention, but sadly it is 
often neglected. According to the reports published by the World Health Organization 
(WHO), in 2017 alone, 220.8 million people required preventive treatment out of which more 
than 102.3 million people were reported to be treated. Although a lot of scientific research is 
being carried out all over the world, with the sole aim of eliminating the disease, there is still 
a long way to go. The lack of funding for research is one of the main culprits in this war 
against parasitic diseases.  
With my dissertation, I would like to take a separate route for treating the parasites 
i.e. preventing  its motility or paralyzing the worm at different stages of the life cycle. For my 
future career, I aim to investigate host-parasite interactions, possibly by selecting targets 
which could interrupt the life cycle of schistosomes, and thus hopefully reduce the chances of 
contracting the disease. 
 
 
 
